What is fibromyalgia

Fibromyalgia also called fibromyalgia syndrome (a set of symptoms), fibro or FMS, is a chronic musculoskeletal pain syndrome that causes muscle pain all over your body accompanied by general fatigue (feeling tired), sleep, memory and mood issues ¹, ², ³, ⁴, ⁵, ⁶, ⁷, ⁸. People who have fibromyalgia often have a heightened sensitivity to pain or experience chronic pain (pain that lasts a long time – possibly your entire life). People with fibromyalgia also have “tender points” on their body ⁹, ¹⁰. Tender points are specific places on the head, the elbows, the shoulders, the knees, the hip joints, and around the neck. These points may be especially painful when pressure is put on them. Researchers believe that fibromyalgia amplifies painful sensations by affecting the way your brain and spinal cord process painful and non-painful signals ¹¹, ¹².

Fibromyalgia was first described in the 19th century. In the 1970s and 1980s, a cause of the disease involving the central nervous system was discovered ¹³. In 1950, Graham introduced the concept of “pain syndrome” in the absence of a specific organic disease ¹⁴. The term “fibromyalgia” was later coined by Smythe and Moldofsky following the identification of regions of extreme tenderness known as “pain points” ¹⁰. These points are defined as areas of hyperalgesia or allodynia when a pressure of about 4 kg/cm² (enough to whiten the nail bed of the fingertip of the examiner) causes pain ⁹. In 1990, the committee of the American College of Rheumatology drew up diagnostic criteria, which have only recently been modified ¹⁵, ³. According to the American College of Rheumatology, the diagnosis of fibromyalgia includes two variables: (1) bilateral pain above and below the waist, characterized by centralized pain, and (2) chronic generalized pain that lasts for at least three months, characterized by pain on palpation in at least 11 of 18 specific body sites (see Figure 1) ¹⁶.

No one knows what causes fibromyalgia. Fibromyalgia symptoms often begin after an event, such as physical trauma, surgery, infection or significant psychological stress. In other cases, symptoms gradually accumulate over time with no single triggering event.

Anyone can get fibromyalgia, but fibromyalgia is most common in middle-aged women than are men (7 times as many women as men). People with rheumatoid arthritis and other autoimmune diseases are particularly likely to develop fibromyalgia. Many people who have fibromyalgia also have tension headaches, temporomandibular joint (TMJ) disorders, irritable bowel syndrome, anxiety and depression.

Fibromyalgia typically develops between the ages of 30 and 60, but can occur in people of any age, including children and the elderly. The prevalence in adolescents has been found to be similar to those in adults in many studies. Between the ages of 20 to 55 years, the cause of generalized musculoskeletal pain in most women is fibromyalgia ¹⁷. Amongst the patients referred to a tertiary care pain clinic, more than 40% met the criteria for fibromyalgia ¹⁸. The risk for fibromyalgia is higher if one has an existing rheumatic disease.

It’s not clear exactly how many people are affected by fibromyalgia, although research has suggested it could be a relatively common condition. Some estimates suggest nearly 1 in 20 people may be affected by fibromyalgia to some degree ³, ¹⁹, ²⁰. The prevalence of fibromyalgia in the United States at 6.4% (7.7% in women and 4.9% in men) ²¹. Studies in Europe and South America show a range from 3.3% to 8.3% that increases with age ²¹, ²².

One of the main reasons it’s not clear how many people are affected is because fibromyalgia can be a difficult condition to diagnose ²³.

There’s no specific test for fibromyalgia and the symptoms can be similar to a number of other conditions.

People with fibromyalgia may also have other symptoms or co-exists with other conditions, such as ²⁴:

• Increased sensitivity to pain.
• Fatigue (extreme tiredness) or chronic fatigue syndrome
• Muscle stiffness
• Difficulty sleeping
• Trouble sleeping
• Morning stiffness
• Migraine and other types of headaches
• Painful menstrual periods
• Tingling or numbness in hands and feet
• Problems with mental processes known as “fibro-fog” – such as problems with memory, thinking and concentration
• Pain in the face or jaw, including disorders of the jaw know as temporomandibular joint syndrome (also known as TMJ disorders).
• Irritable bowel syndrome (IBS) – a digestive condition that causes abdominal pain, constipation and bloating
• Interstitial cystitis or painful bladder syndrome
• Anxiety
• Depression
• Postural tachycardia syndrome

There will be times when your fibromyalgia may “flare up” and your symptoms will be worse. Other times, you will feel much better. The good news is that your symptoms can be managed.

Fibromyalgia is a condition that is often misunderstood. But your symptoms aren’t “all in your head”. Scientific research has shown that fibromyalgia is a real syndrome that causes real pain. Don’t let anyone discourage you from getting a diagnosis and treatment for your symptoms.

You cannot prevent fibromyalgia because no one is sure what causes it.

To date, no objective tests or biomarkers with sufficient diagnostic accuracy have been identified, and current tests can only indicate a predisposition to fibromyalgia.

There is no cure for fibromyalgia, but fibromyalgia can be effectively treated and managed with a variety of medications and self-care strategies. It’s important for you to be responsible for your health. Getting enough sleep, exercising, stress-reduction and eating well may also help. No one treatment works for all symptoms, but trying a variety of treatment strategies can have a cumulative effect.

Exercise seems to be the most effective treatment, including yoga, tai chi, or other low-impact aerobic activity. Acupuncture, chiropractic, and massage may help ease symptoms. Psychotherapy may help patients manage stress and anxiety. A sleep specialist may help patients address sleep disorders.

Medications can help reduce the pain of fibromyalgia and improve sleep. Three drugs are FDA-approved for fibromyalgia: Duloxetine (Cymbalta) and Milnacipran (Savella) adjust brain chemicals to ease widespread pain and fatigue associated with fibromyalgia and Pregabalin (Lyrica), which blocks overactive nerve cells involved in pain. Pregabalin (Lyrica) was the first drug approved by the Food and Drug Administration to treat fibromyalgia.

• Pain relievers. Over-the-counter pain relievers such as acetaminophen (Tylenol, others), ibuprofen (Advil, Motrin IB, others) or naproxen sodium (Aleve, others) may be helpful. Opioid medications are not recommended, because they can lead to significant side effects and dependence and will worsen the pain over time.
• Older drugs, such as amitryptiline (Elavil), cyclobenzaprine (Flexeril) and other antidepressants may be used to help promote sleep. Opioids and sleep medicines like zolpidem (Ambien) are not recommended for use in treating fibromyalgia symptoms.
• Anti-seizure drugs. Medications designed to treat epilepsy are often useful in reducing certain types of pain. Gabapentin (Neurontin) is sometimes helpful in reducing fibromyalgia symptoms.

Self-care is critical in the management of fibromyalgia:

• Stress management. Develop a plan to avoid or limit overexertion and emotional stress. Allow yourself time each day to relax. That may mean learning how to say no without guilt. But try not to change your routine completely. People who quit work or drop all activity tend to do worse than do those who remain active. Try stress management techniques, such as deep-breathing exercises or meditation.
• Sleep hygiene. Because fatigue is one of the main components of fibromyalgia, getting good quality sleep is essential. In addition to allotting enough time for sleep, practice good sleep habits, such as going to bed and getting up at the same time each day and limiting daytime napping.
• Exercise regularly. At first, exercise may increase your pain. But doing it gradually and regularly often decreases symptoms. Appropriate exercises may include walking, swimming, biking and water aerobics. A physical therapist can help you develop a home exercise program. Stretching, good posture and relaxation exercises also are helpful.
• Pace yourself. Keep your activity on an even level. If you do too much on your good days, you may have more bad days. Moderation means not overdoing it on your good days, but likewise it means not self-limiting or doing too little on the days when symptoms flare.
• Maintain a healthy lifestyle. Eat healthy foods. Do not use tobacco products. Limit your caffeine intake. Do something that you find enjoyable and fulfilling every day.

Self-Management Resources:

• You can join a self-management education class, which helps people with arthritis or other conditions—including fibromyalgia—be more confident in how to control their symptoms, how to live well and understand how the condition affects their lives. You can find more info on Self-Management Resource Center here: https://www.selfmanagementresource.com/
• Chronic Disease Self-Management Program is an effective self-management education workshop for people with chronic health problems. The program specifically addresses arthritis, diabetes, lung and heart disease, but teaches skills useful for managing a variety of chronic diseases. This program was developed at Stanford University. Locate a Chronic Disease Self-Management Program in your area here: http://www.eblcprograms.org/evidence-based/map-of-programs/

If you think you have fibromyalgia, visit your doctor. Treatment is available to ease some of its symptoms, although they’re unlikely to disappear completely.

It’s important to have a health care team that understands fibromyalgia and has experience treating fibromyalgia. Your healthcare team will probably include your family doctor, a rheumatologist, and a physical therapist. Other health care professionals may help you manage other symptoms, such as mood or sleep problems. However, the most important member of your health care team is you. The more active you are in your care, the better you will feel.

Doctors usually treat fibromyalgia with a combination of treatments, which may include:

• Medications, including prescription drugs and over-the-counter pain relievers.
• Aerobic exercise and muscle strengthening exercise.
• Patient education classes, usually in primary care or community settings.
• Stress management techniques such as meditation, yoga, and massage.
• Good sleep habits to improve the quality of sleep.
• Cognitive behavioral therapy (CBT) to treat underlying depression. CBT is a type of talk therapy meant to change the way people act or think.

In addition to medical treatment, people can manage their fibromyalgia with the self-management strategies described below, which are proven to reduce pain and disability, so they can pursue the activities important to them.

However, there isn’t one treatment plan that works best for every person who has fibromyalgia. You’ll have to work with your care team to create a plan that’s right for you. After all, nobody knows more than you do about your feelings, your actions, and how your fibromyalgia symptoms affect you.

Key facts ²⁵

• Fibromyalgia affects two – four percent of people, women more often than men.
• Fibromyalgia is NOT an autoimmune, inflammation inflammation, joint or muscle disorder based illness, but research suggests the nervous system is involved.
• Doctors diagnose fibromyalgia based on all the patient’s relevant symptoms (what you feel), no longer just on the number of tender places during an examination.
• There is no test to detect this disease, but you may need lab tests or X-rays to rule out other health problems.
• Though there is no cure, medications can reduce symptoms in some patients.
• Patients also may feel better with proper self-care, such as exercise and getting enough sleep.

Figure 1. Fibromyalgia tender points

Footnote: The dots indicate the 18 tenderness points important for the diagnosis of fibromyalgia.

Is fibromyalgia real?

This is the top misconception where people think fibromyalgia isn’t a real medical problem or that it is “all in your head.” Despite there’s a lot that’s unknown about fibromyalgia, researchers have learned more about it in just the past few years.

In people who have fibromyalgia, the brain and spinal cord process pain signals differently. As a result, they react more strongly to touch and pressure, with a heightened sensitivity to pain. It is a real physiological and neurochemical problem.

The power of the mind is a real factor in pain perception. For example, studies have shown that anxiety that occurs in anticipation of pain is often more problematic than the pain experience itself. In that sense, the mind has a negative impact on symptoms. It takes lifestyle changes and small steps toward achieving wellness.

Why do I feel depressed?

Depression or anxiety may occur as a result of your constant pain and fatigue, or the frustration you feel with the condition. It is also possible that the same chemical imbalances in the brain that cause mood changes also contribute to fibromyalgia.

Does fibromyalgia cause permanent damage?

No. Although fibromyalgia causes symptoms that can be very painful and uncomfortable, your muscles and organs are not being damaged. Fibromyalgia is not life-threatening, but it is chronic (ongoing and lasting more than 3 months). Although there is no cure, there are many things you can do to feel better.

Is it hard to diagnose fibromyalgia?

Unfortunately, it can take years for some people who have fibromyalgia to get a correct diagnosis. This can happen for many reasons. The main symptoms of fibromyalgia are generalized muscle pain and fatigue. These are also common symptoms of many other health problems, such as chronic fatigue syndrome, hypothyroidism, and arthritis.

Currently, there is no laboratory test or X-ray that can diagnose fibromyalgia.

It may take some time for your doctor to understand all of your symptoms and rule out other health problems so he or she can make an accurate diagnosis. As part of this process, your family doctor may consult with a rheumatologist. This type of doctor specializes in pain in the joints and soft tissue.

Juvenile fibromyalgia syndrome

Juvenile fibromyalgia syndrome also called juvenile primary fibromyalgia syndrome, is a chronic condition characterized by symptoms of chronic diffuse musculoskeletal pain and multiple painful tender points on palpation ²⁶. Juvenile fibromyalgia syndrome is often accompanied by fatigue, disorders of sleep, chronic headaches, irritable bowel syndrome, and subjective soft tissue swelling. The complexity of the presenting clinical picture in juvenile fibromyalgia syndrome has not been sufficiently defined in the literature ²⁶. Similarities to adult fibromyalgia syndrome in juvenile fibromyalgia syndrome are often difficult to compare, because many of the symptoms are “medically unexplained” and often overlap frequently with other medical conditions. However, a valid diagnosis of juvenile fibromyalgia syndrome often decreases parents’ anxiety, reduces unnecessary further investigations, and provides a rational framework for a management plan. The diagnostic criteria proposed by Yunus and Masi in 1985 to define juvenile fibromyalgia syndrome were never validated or critically analyzed. In most cases, the clinical diagnosis is based on the history, the physical examination that demonstrates general tenderness (muscle, joints, tendons), the absence of other pathological conditions that could explain pain and fatigue, and the normal basic laboratory tests. Research and clinical observations defined that juvenile fibromyalgia syndrome may have a chronic course that impacts the functional status and the psychosocial development of children and adolescents.

The reported prevalence of juvenile fibromyalgia syndrome varies widely probably reflecting differences in ethnicity, socio-cultural background, psychological traits of the population and diverse methodologies that have been used in the published studies ²⁷. The prevalence of juvenile fibromyalgia syndrome reported in the literature in different countries is summarized in Table 1. Juvenile fibromyalgia syndrome has a prevalence around 1-6%, more common in girls, and can be seen in children of all ages.

Table 1. Prevalence of juvenile fibromyalgia syndrome in children and adolescents: review of the literature

Abbreviations: JFMS = juvenile fibromyalgia syndrome; FM = fibromyalgia; (*) International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes to identify fibromyalgia cases (ICD code 729.1).

Juvenile fibromyalgia syndrome in children and adolescents treatments

Goals of treatment should be pain relief, restoration of functioning, reduction of school absenteeism, dissolving social isolation, strengthening self-awareness, mobilizing domestic resources and the development of strategies for coping with pain. The inclusion of the family, the training of strategies in everyday life and the treatment of mental comorbidities are also important ²⁸.

Evidence-based treatment guidelines in ibromyalgia include those developed by the American Pain Society (APS) in 2005 ²⁹ and the European League Against Rheumatism (EULAR) in 2008 ³⁰.

However, they were developed before FDA approved any medications for treating fibromyalgia and substantial heterogeneity exists between the recommendations. Furthermore, the studies evaluated during the development of these guidelines were not directly comparable as a result of variations in study design and short duration that limit their general applicability in clinical practice ³¹.

Little is known regarding treatment choices of youth diagnosed with juvenile fibromyalgia syndrome as they move into young adulthood. The management of juvenile fibromyalgia syndrome is centered on the issues of education, behavioral and cognitive change (cognitive-behavioral therapy [CBT]) with a strong emphasis on physical exercise), and a relatively minor role for pharmacological treatment with medications such as muscle relaxants, analgesics and tricyclic agents ³². Any patient being treated with a medication should be carefully evaluated for both efficacy as well as side effects, and medications should be discontinued unless there is evidence for definite benefit. More controlled studies are needed to investigate the effectiveness of these complementary methods to assist treatment providers in giving evidence-based treatment recommendations.

A recent Cochrane review has concluded that psychological treatments may improve pain control for children with a variety of pain conditions, including muscle pain, abdominal pain, headaches and fibromyalgia syndrome ³³. Therefore, it appears that CBT should be offered as a preferred modality of non-pharmacological treatment for juvenile fibromyalgia syndrome.

If disease development is assumed to be linked to the family background, hospitalization aimed to temporarily isolate the patient from his or her home environment should be taken into consideration ³⁴.

Prompt recognition of juvenile fibromyalgia syndrome may decrease problems for pediatric patients with chronic pain, while pediatric primary care providers’ lack of familiarity with juvenile fibromyalgia syndrome can cause a delay in diagnosis and management ³⁵.

Fibromyalgia in children and adolescents prognosis

Initial studies indicated a positive long-term prognosis for juvenile fibromyalgia syndrome ³⁶. By contrast, studies in subjects with juvenile fibromyalgia syndrome recruited from hospital settings have shown a chronic and fluctuating course, with symptoms persisting in ~70% of young people ³⁷.

One controlled study published in 2010 of patients with juvenile fibromyalgia syndrome and matched healthy controls (mean age, 15 years) showed that about 50% of patients with juvenile fibromyalgia met the full American College of Rheumatology criteria for fibromyalgia at ~4 years follow-up (mean age, 19 years), and >70% had continuing symptoms of pain, fatigue or sleep difficulty ³⁷.

Several authors report different prognoses between adults and youths with fibromyalgia ³⁸. They suggested that the early detection of juvenile fibromyalgia syndrome is an indication of a better prognosis ³⁹, with significant gains in quality of life ⁴⁰, and functionality for individuals who receive adequate treatment, whereas those with widespread pain that are not treated adequately have a greater chance of developing fibromyalgia ⁴¹. On the other hand, in a large prospective longitudinal study of juvenile fibromyalgia syndrome patients, Kashikar-Zuck et al. ⁴² found that the majority of adolescent patients (~80%) with juvenile fibromyalgia syndrome seen in a pediatric specialty care setting continued to report persistent pain and other FM symptoms as they transitioned into young adulthood.

In conclusion, most of youth with juvenile fibromyalgia syndrome continue to experience symptoms into adulthood, which highlights the importance of early diagnosis and intervention. However, more research into the variability of outcomes within the juvenile primary fibromyalgia syndrome group, with closer examination of risk and protective factors associated with future outcomes is essential to designing focused interventions.

Fibromyalgia signs and symptoms

Fibromyalgia has many symptoms that tend to vary from person to person. The main symptom is widespread pain. The pain associated with fibromyalgia often is described as a constant dull ache that has lasted for at least three months. To be considered ‘widespread pain’, the pain must occur on both sides of your body and above and below your waist.

Symptoms of fibromyalgia can include the following:

• Increased sensitivity to pain.
• Fatigue (extreme tiredness) or chronic fatigue syndrome
• A deep ache or a burning pain that gets worse because of activity, stress, weather changes, or other factors.
• Muscle stiffness or spasms.
• Pain that moves around your body.
• Feelings of numbness or tingling in your hands, arms, or legs.
• Feeling very tired or fatigued (out of energy), even when you get enough sleep. People with fibromyalgia often awaken tired, even though they report sleeping for long periods of time. Sleep is often disrupted by pain, and many patients with fibromyalgia have other sleep disorders, such as restless legs syndrome and sleep apnea.
• Trouble sleeping.

There may be periods when your symptoms get better or worse, depending on factors such as:

• your stress levels
• changes in the weather
• how physically active you are

People who have fibromyalgia often also have one or more of the following:

• Anxiety.
• Depression.
• Irritable bowel syndrome (IBS).
• Restless legs syndrome.
• Increased sensitivity to odors, bright lights, loud noises, or medicines.
• Headaches, migraines, or jaw pain.
• Dry eyes or mouth.
• Dizziness and problems with balance.
• Problems with memory or concentration (sometimes called the “fibro fog”).
• For women, painful menstrual periods.

If you think you have fibromyalgia, visit your doctor. Treatment is available to ease some of the symptoms, although it’s unlikely they’ll ever disappear completely.

The main symptoms of fibromyalgia are outlined below.

Widespread pain

If you have fibromyalgia, one of the main symptoms is likely to be widespread pain. This may be felt throughout your body, but could be worse in particular areas, such as your back or neck. The pain is likely to be continuous, although it may be better or more severe at different times.

The pain could feel like:

• an ache
• a burning sensation
• a sharp, stabbing pain

Temporo-mandibular joint pain (TMJ pain)

This Temporo-mandibular Joint Dysfunction Syndrome, sometimes referred to as TMJD, causes tremendous face and head pain in one quarter of fibromyalgia patients. However, a 1997 report indicates that as many as 90% of fibromyalgia patients may have jaw and facial tenderness that could produce, at least intermittently, symptoms of temporo-mandibular joint dysfunction. Most of the problems associated with this condition are thought to be related to the muscles and ligaments surrounding the joint and not necessarily the joint itself.

Extreme sensitivity

Fibromyalgia can make you extremely sensitive to pain all over your body, and you may find that even the slightest touch is painful. If you hurt yourself – such as stubbing your toe – the pain may continue for much longer than it normally would.

You may hear the condition described in the following medical terms:

• Hyperalgesia – when you’re extremely sensitive to pain
• Allodynia – when you feel pain from something that shouldn’t be painful at all, such as a very light touch

You may also be sensitive to things such as smoke, certain foods and bright lights. Being exposed to something you’re sensitive to can cause your other fibromyalgia symptoms to flare up.

Multiple Chemical Sensitivity Syndrome

Sensitivities to odors, noise, bright lights, medications and various foods is common in roughly 50% of fibromyalgia patients.

Stiffness

Fibromyalgia can make you feel stiff. The stiffness may be most severe when you’ve been in the same position for a long period of time – for example, when you first wake up in the morning.

It can also cause your muscles to spasm, which is when they contract (squeeze) tightly and painfully.

Fatigue

Fibromyalgia can cause fatigue (extreme tiredness). This can range from a mild, tired feeling to the exhaustion often experienced during a flu-like illness.

Severe fatigue may come on suddenly and can drain you of all your energy. If this happens, you may feel too tired to do anything at all.

Poor sleep quality

Fibromyalgia can affect your sleep. You may often wake up tired, even when you’ve had plenty of sleep. This is because the condition can sometimes prevent you from sleeping deeply enough to refresh you properly.

You may hear this described as “non-restorative sleep”.

Cognitive problems (‘fibro-fog’)

Cognitive problems commonly referred to as “fibro fog” are issues related to mental processes (cognitive difficulties), such as thinking and learning. If you have fibromyalgia, you may have:

• trouble remembering and learning new things
• problems with attention (the ability to focus) and concentration on mental tasks
• slowed or confused speech

Headaches

If fibromyalgia has caused you to experience pain and stiffness in your neck and shoulders, you may also have frequent headaches.

These can vary from being mild headaches to severe migraines, and could also involve other symptoms, such as nausea (feeling sick).

Irritable bowel syndrome (IBS)

Some people with fibromyalgia also develop irritable bowel syndrome (IBS).

IBS is a common digestive condition that causes pain and bloating in your stomach. It can also lead to constipation or diarrhoea.

Other symptoms

Other symptoms that people with fibromyalgia sometimes experience include:

• dizziness and clumsiness
• feeling too hot or too cold – this is because you’re not able to regulate your body temperature properly
• restless legs syndrome (an overwhelming urge to move your legs)
• tingling, numbness, prickling or burning sensations in your hands and feet (pins and needles, also known as paresthesia)
• in women, unusually painful periods
• anxiety
• depression

Depression

In some cases, having the condition can lead to depression. This is because fibromyalgia can be difficult to deal with, and low levels of certain hormones associated with the condition can make you prone to developing depression.

Depression can cause many symptoms, including:

• constantly feeling low
• feeling hopeless and helpless
• losing interest in the things you usually enjoy

If you think you may be depressed, it’s important to get help from your doctor or your fibromyalgia healthcare professional, if you’ve been seeing one.

What are the complications of fibromyalgia?

Fibromyalgia can cause pain, disability, and lower quality of life. US adults with fibromyalgia may have complications such as:

• More hospitalizations. If you have fibromyalgia you are twice as likely to be hospitalized as someone without fibromyalgia.
• Lower quality of life. Women with fibromyalgia may experience a lower quality of life.
• Higher rates of major depression. Adults with fibromyalgia are more than 3 times more likely to have major depression than adults without fibromyalgia. Screening and treatment for depression is extremely important.
• Higher death rates from suicide and injuries. Death rates from suicide and injuries are higher among fibromyalgia patients, but overall mortality among adults with fibromyalgia is similar to the general population.
• Higher rates of other rheumatic conditions. Fibromyalgia often co-occurs with other types of arthritis such as osteoarthritis, rheumatoid arthritis, systemic lupus erythematosus, and ankylosing spondylitis.

Fibromyalgia causes

The exact cause of fibromyalgia is unknown, but fibromyalgia is thought to be related to abnormal levels of certain chemicals in the brain and changes in the way the central nervous system (brain, spinal cord and nerves) processes pain messages carried around the body ⁴³, ⁴⁴, ⁴⁵, ¹, ²³,⁴⁶, ⁴⁷. In addition, the brain’s pain receptors seem to develop a sort of memory of the pain and become sensitized, meaning they can overreact to painful and nonpainful signals.

It’s also suggested that some people are more likely to develop fibromyalgia because of genes inherited from their parents. Fibromyalgia tends to run in families, there may be certain genetic mutations that may make you more susceptible to developing fibromyalgia.

There is most often some triggering factor that sets off fibromyalgia. It may be spine problems, arthritis, injury, infections or other type of physical stress, such as a car accident. Emotional stress and prolonged psychological stress also may trigger fibromyalgia. The result is a change in the way your body “talks” with your spinal cord and brain. Levels of brain chemicals and proteins may change. More recently, fibromyalgia has been described as Central Pain Amplification disorder, meaning the volume of pain sensation in the brain is turned up too high.

In many cases, fibromyalgia appears to be triggered by a physically or emotionally stressful event, such as:

• an injury or infection
• giving birth
• having an operation
• the breakdown of a relationship
• the death of a loved one
• illness or other diseases
• post-traumatic stress disorder (PTSD)
• repetitive injuries
• obesity.

Here are some of the main factors thought to contribute to fibromyalgia:

Abnormal pain messages

One of the main theories is that people with fibromyalgia have developed changes in the way the central nervous system processes the pain messages carried around the body. This could be due to changes to chemicals in the nervous system.

The central nervous system (brain, spinal cord and nerves) transmits information all over your body through a network of specialized cells. Changes in the way this system works may explain why fibromyalgia results in constant feelings of, and extreme sensitivity to, pain.

Chemical imbalances

Research has found that people with fibromyalgia have abnormally low levels of the hormones serotonin, noradrenaline and dopamine in their brains.

Low levels of these hormones may be a key factor in the cause of fibromyalgia, as they’re important in regulating things such as:

• mood
• appetite
• sleep
• behavior
• your response to stressful situations

These hormones also play a role in processing pain messages sent by the nerves. Increasing the hormone levels with medication can disrupt these signals.

Some researchers have also suggested that changes in the levels of some other hormones, such as cortisol (which is released when the body is under stress), may contribute to fibromyalgia.

Sleep problems

It’s possible that disturbed sleep patterns may be a cause of fibromyalgia, rather than just a symptom.

Fibromyalgia can prevent you from sleeping deeply and cause fatigue (extreme tiredness). People with the condition who sleep badly can also have higher levels of pain, suggesting that these sleep problems contribute to the other symptoms of fibromyalgia.

Genetics

Research has suggested that genetics may play a small part in the development of fibromyalgia, with some people perhaps more likely than others to develop the condition because of their genes, although there is no evidence of a definitive gene has been found ⁴⁸. Currently, about 100 genes that regulate pain are believed to be relevant to pain sensitivity or analgesia. The main genes are those encoding for voltage-dependent sodium channels, GABAergic pathway proteins, mu-opioid receptors, catechol-O-methyltransferase and GTP cyclohydrolase 1 ⁴⁹. Further studies are needed to understand the role of these genes in chronic pain conditions such as fibromyalgia.

Associated conditions

There are several other conditions often associated with fibromyalgia. Generally, these are rheumatic conditions (affecting the joints, muscles and bones), such as:

• Osteoarthritis – when damage to the joints causes pain and stiffness
• Lupus – when the immune system mistakenly attacks healthy cells and tissues in various parts of the body
• Rheumatoid arthritis – when the immune system mistakenly attacks healthy cells in the joints, causing pain and swelling
• Ankylosing spondylitis – pain and swelling in parts of the spine
• Temporomandibular disorder – a condition that can cause pain in the jaw, cheeks, ears and temples

Conditions such as these are usually tested for when diagnosing fibromyalgia.

Possible triggers

Fibromyalgia is often triggered by a stressful event, including physical stress or emotional (psychological) stress. Possible triggers for the condition include:

• an injury
• a viral infection
• giving birth
• having an operation
• the breakdown of a relationship
• being in an abusive relationship
• the death of a loved one

However, in some cases, fibromyalgia doesn’t develop after any obvious trigger.

Risk factors for fibromyalgia

Known risk factors for fibromyalgia include:

• Age. Fibromyalgia can affect people of all ages, including children. However, most people are diagnosed during middle age and you are more likely to have fibromyalgia as you get older.
• Lupus or Rheumatoid Arthritis. If you have lupus or rheumatoid arthritis (RA), you are more likely to develop fibromyalgia.

Some other factors have been weakly associated with onset of fibromyalgia, but more research is needed to see if they are real. These possible risk factors include:

• Sex. Women are seven times as likely to have fibromyalgia as men.
• Stressful or traumatic events, such as car accidents, post-traumatic stress disorder (PTSD).
• Repetitive injuries. Injury from repetitive stress on a joint, such as frequent knee bending.
• Illness (such as viral infections).
• Family history. You may be more likely to develop fibromyalgia if a parent or sibling also has fibromyalgia.
  
• Obesity.

Fibromyalgia pathophysiology

Fibromyalgia appears to be related to a pain-processing problem in your brain ¹⁷, ⁴³, ⁷. In most cases, people with fibromyalgia become hypersensitive to the perception of pain ⁷. The constant hypervigilance to pain can also be associated with psychological problems ¹⁷.

Abnormalities noted in fibromyalgia include ¹⁷:

• Elevated levels of the excitatory neurotransmitters like glutamate and substance P
• Diminished levels of serotonin and norepinephrine (also known as noradrenaline) in the descending anti-nociceptive pathways in the spinal cord
• Prolonged enhancement of pain sensations
• Dysregulation of dopamine
• Alteration in the activity of brain endogenous opioids.

Fibromyalgia is more common in women than men because of the following ¹⁷:

• Higher levels of anxiety
• Use of maladaptive coping methods
• Altered behavior in response to pain
• Higher levels of depression
• Altered input to the central nervous system (brain and spinal cord)
• Hormonal effects of the menstrual cycle

The main alterations observed in fibromyalgia are dysfunctions in mono-aminergic neurotransmission, leading to elevated levels of excitatory neurotransmitters, such as glutamate and substance P, and decreased levels of serotonin and norepinephrine in the spinal cord at the level of descending anti-nociceptive pathways. Other anomalies observed are dopamine dysregulation and altered activity of endogenous cerebral opioids. Taken together, these phenomena seem to explain the central physiopathology of fibromyalgia ⁵⁰.

Over the years, peripheral pain generators have also been recognized as a possible cause of fibromyalgia. In this case, patients manifest symptoms such as cognitive impairment (“fibro-fog”), chronic fatigue, sleep disturbances, intestinal irritability, interstitial cystitis and mood disorders ⁵¹, ⁵².

Peripheral abnormalities may contribute to increased nociceptive tonic supply in the spinal cord, which results in central sensitization. Other factors that appear to be involved in the pathophysiology of fibromyalgia are neuroendocrine factors, genetic predisposition, oxidative stress and environmental and psychosocial changes ⁵³, ⁵⁴.

Pain-processing problem in the brain

Fibromyalgia appears to be related to a pain-processing problem in your brain also known as central sensitization ¹⁷, ⁴³, ⁷. In most cases, people with fibromyalgia become hypersensitive to the perception of pain ⁷. Central sensitization refers to a neuronal signal amplification mechanism within the central nervous system (brain and spinal cord) that leads to a greater perception of pain ⁵⁵. For this reason, patients with fibromyalgia present an increase in the receptive field of pain, allodynia and hyperalgesia. Central sensitization is also implicated in persistent and chronic pain. Although central sensitization plays an important role in fibromyalgia, it is even more important to understand the initial cause, that is, the persistent nociceptive input associated with tissue damage, including peripheral sensitization ⁵⁶. According to Vierck ⁵⁶, if peripheral pain generators can be blocked, the symptoms of fibromyalgia should disappear or not even develop. Despite this, researchers focus more on central sensitization as the mechanism of pain sensitivity because there is less evidence to support the involvement of peripheral pain tissue abnormalities and nociceptive processes in fibromyalgia ⁵⁷. Brosschot et al. ⁵⁸ observed that fibromyalgia patients were selectively attentive to information regarding the body and the environment in relation to pain. In this regard, they introduced the term “cognitive-emotional sensitization” to explain how selective attention to certain body pain can increase the perception of that pain. Pain sensitivity is also linked to social groups. It has been suggested that the mechanism that underlies “interpersonal sensitization” could be linked to the shared neuronal representation of the experience of pain. In other words, a feed-forward effect occurs in which a family, in an attempt to reduce painful behaviors in one of its members, actually creates a state of anxiety in the person concerned by increasing the perception of pain ⁵⁹, ⁶⁰.

Patients with fibromyalgia present a lower pain threshold that generates a condition of diffuse hyperalgesia and/or allodynia. This indicates that there may be a problem with the amplification of pain or with sensory processing in the central nervous system (brain and spinal cord). These fibromyalgia phenomena have been confirmed in clinical studies that used functional neuroimaging or measured alterations in neurotransmitter levels that influence sensory transmission and pain ⁶¹, ⁶², ¹. It was also observed that treatments with drugs aimed at increasing anti-nociceptive neurotransmitters in the central nervous system (brain and spinal cord) or at lowering the levels of pro-nociceptive excitatory neurotransmitters, such as glutamate, were able to improve these conditions in patients with fibromyalgia. Exercise has also proved useful for increasing anti-nociceptive neurotransmitters and reducing glutamate ⁶³, ⁶⁴. In contrast, patients with fibromyalgia do not respond to non-steroidal anti-inflammatory drug (NSAID) therapies aimed at resolving acute pain or pain induced by tissue damage or inflammation.

The chronic pain typical of fibromyalgia is due to alterations in central and peripheral sensitization. Over the years, researchers have searched for biomarkers that are capable of detecting these changes. In particular, they focused on factors capable of acting on the growth and survival of nerve cells, such as nerve growth factor (NGF). The nerve growth factor (NGF) is indeed involved in promoting the growth, proliferation and survival of sensory neurons that transmit pain, temperature and tactile sensations ⁶⁵. Data obtained in earlier studies showed an increase in nerve growth factor (NGF) in the cerebrospinal fluid of fibromyalgia patients ⁶⁶. However, these data disagree with those from a recent study in patients, in which plasma NGF levels were not found to differ between fibromyalgia and control subjects. In this regard, different statistical methods were used, which nonetheless led to the same conclusions ⁶⁷. Further studies are therefore needed to understand the involvement of NGF in the pathophysiology of fibromyalgia.

Inflammation and Immunity

Increasing evidence indicates that neurogenic-derived inflammatory processes occurring in the peripheral tissues, spinal cord and brain are also responsible for the pathophysiology of fibromyalgia ⁶⁸, ⁶⁹, ⁷⁰. The release of biologically active agents, such as chemokines and cytokines, leads to the activation of the innate and adaptive immune system. All of this translates into many of the peripheral clinical features reported by patients with fibromyalgia, such as swelling and dysesthesia, which can also affect central symptoms, including cognitive changes and fatigue. In addition, the physiological mechanisms related to stress and emotions are considered to be upstream drivers of neurogenic inflammation in fibromyalgia ⁷¹.

Studies conducted in patients have confirmed that inflammation is involved in fibromyalgia. Fibromyalgia patients have been shown to have enhanced circulating inflammatory cytokines and inflammatory cytokines released by circulating immune cells ⁷⁰, ⁷².

Kadetoff et al. ⁷³ described an increased concentration of IL-8 in the cerebrospinal fluid of fibromyalgia patients compared to healthy subjects. This finding could be due to the activation of glial cells, which play an important role in the central sensitization process, as they are activated in response to excitatory synaptic signals (glutamate) ⁷⁴. Furthermore, since the synthesis of IL-8 is dependent on orthosympathetic activation, this could help explain the correlation between stress and fibromyalgia symptoms ⁷⁵. In addition to this, some studies have shown an increase in serum concentrations of IL-6, IL-8, IL-1β and TNF-α in individuals with fibromyalgia, although no clear correlation with symptom severity has been identified, except, perhaps, for IL-6 ⁷⁰, ⁷⁶, ⁷⁷, ⁷⁸. It appears that immune cells such as mast cells, monocytes and neutrophils, as mediators of inflammation processes, may also have a function in defining an inflammatory substrate of fibromyalgia ⁷⁹. In animals, macrophages located in the muscle have been shown to contribute to the development of chronic widespread muscle pain. For example, the removal of macrophages at the acid injection site through a local injection of clodronate liposomes is capable of preventing the development of exercise-induced hyperalgesia ⁸⁰. Another observation is that pro-inflammatory cytokines, such as interleukins (IL-1β, IL-6) and tumor necrosis factor (TNFα), can activate and sensitize nociceptors, induce pain in humans and trigger hyperalgesia in animals. Another potential source of these cytokines is adipose tissue; many studies suggest that diffuse or multifocal pain is more common in obese individuals ⁸¹ and obese animals show enhanced nociceptive responses ⁸², ⁸³. Therefore, pro-inflammatory cytokines could play a role in the generation of chronic muscle pain, including fibromyalgia.

Smart et al. ⁸⁴ described a subgroup of fibromyalgia patients characterized by ANA (anti-nuclear antibody) positivity, with the speckled pattern clearly predominating. The use of the Smart Index, which corrects the erythrocyte sedimentation rate value in relation to age, revealed that ANA-positive fibromyalgia patients had a more pronounced inflammatory response profile than the ANA-negative subgroup, suggesting that autoimmunity potentially contributes to sub-inflammatory fibromyalgia ⁸⁴.

Genetic factors

Over the years, studies have shown the potential involvement of genetic factors in the onset of fibromyalgia ⁸⁵, ⁸⁶. Linkage studies have shown a correlation rate of 50% between genetic variants and the development of chronic pain ⁸⁷. Currently, about 100 genes that regulate pain are believed to be relevant to pain sensitivity or analgesia. The main genes are those encoding for voltage-dependent sodium channels, GABAergic pathway proteins, mu-opioid receptors, catechol-O-methyltransferase and GTP cyclohydrolase 1 ⁴⁹. The small sample sizes did not allow the authors to confirm an association between single nucleotide polymorphisms and fibromyalgia susceptibility. However, a genome-wide linkage scan study found that first-degree relatives had an increased risk of developing fibromyalgia, reinforcing the genetic hypothesis. The serotonin transporter gene (SLC64A4) and the transient receptor 2 potential vanillic channel gene (TRPV2) are the major genes responsible for pain susceptibility in fibromyalgia ⁸⁸. SLC64A4 is characterized by a single nucleotide polymorphism and is associated with chronic pain conditions (for example, mandibular joint disorder), as well as increased levels of depression and psychological disorders related to an alteration in serotonin reuptake ⁸⁹. The TRPV2 gene is expressed in mechano- and thermo-responsive neurons in the dorsal root and trigeminal ganglia and appears to be responsible for reducing the pain threshold in fibromyalgia patients ⁹⁰.

Other genetic polymorphisms that have been identified and associated with fibromyalgia susceptibility are in the serotonin transporter (5-HTT), catechol-O-methyltransferase (COMT) and serotonin 2A (5-HT2A) genes. However, subsequent meta-analyses could only confirm that the 102T/C polymorphism in the 5-HT2A receptor is connected with fibromyalgia ⁹¹. Therefore, further studies are needed to understand the role of these genes in chronic pain conditions such as fibromyalgia. A genome-wide association and copy number variant study in 952 fibromyalgia cases and 644 controls revealed the existence of two variables associated with fibromyalgia. One variable is the single nucleotide polymorphism rs11127292 in a gene similar to myelin transcription factor 1 (MYT1L), which is responsible for neuronal differentiation and involved in cognitive alterations. The second is an intron copy number variable in the neurexin 3 (NRXN3) gene, which normally acts as a receptor and cell adhesion molecule in the nervous system, and variations in this gene are involved in autism spectrum disorder ⁹².

Other researchers analyzed 350 other genes that are specifically involved in pain treatment. Among these is the TAAR1 gene, which mediates the availability of dopamine, whose reduction can increase the sensitivity to pain typical of fibromyalgia ⁹³. Another widely studied gene is RGS4, which is expressed in the dorsal horn of the spinal cord, the locus coeruleus and the nuclei of the bed of the stria terminalis, and is responsible for modulating the descending inhibition of pain perception ⁹⁴. One gene studied and related to pain disorders is CNR1, which encodes the cannabinoid receptor CB-1 ⁹⁵, ⁹⁶. Another gene presumably involved in central sensitization is GRIA4, which mediates the rapid excitatory transmission of nociceptive signals in the central nervous system ⁹⁷. Taken together, these studies have increased the current knowledge on fibromyalgia and support genes as a potential factor in the pathogenesis of this disease. However, as fibromyalgia remains a multifactorial disease, further studies are needed to examine haplotypes and combinations of different variants that could influence its development.

Endocrine factors

The role of stress in the worsening of fibromyalgia symptoms has been widely described from an epidemiological point of view through both self-reports and clinical questionnaires. On the basis of these data, the hypothalamic–pituitary–adrenal axis, central to the stress response, was examined. Despite the discrepancy between different studies on possible alterations in plasma cortisol levels in fibromyalgia patients, dysregulation of its circadian variation is frequently observed. In particular, flattening of the plasma cortisol concentration curve was observed during the day: this seems to manifest itself through a milder and more gradual descent compared to the morning peak of maximum concentration or through a lowering of the peak itself ⁹⁸, ⁹⁹, ¹⁰⁰, ¹⁰¹, ¹⁰². In addition to this, decreased cortisol secretion has also been described in response to adrenocorticotropic hormone (ACTH) tests ¹⁰³. The hypothalamic–pituitary–adrenal axis (HPA) comprises neurotransmitter and neuroendocrine response systems to stress and can be activated in fibromyalgia ¹⁰⁴. This system may explain some of the symptoms seen in fibromyalgia.

A patient study looked at levels of corticotropin-releasing factor (CRF) in cerebrospinal fluid (CSF), heart rate variability (HRV) and pain symptoms (e.g., fatigue and depression) in subjects with fibromyalgia. The results obtained in this study showed that corticotropin-releasing factor (CRF) levels were associated with sensory and affective pain symptoms but not with symptoms of fatigue. Furthermore, an increase in heart rate variability (HRV) was associated with an increase in CRF and pain in patients with fibromyalgia. These results were subsequently adjusted for age, sex and depressive symptoms, and a correlation between CRF levels and sensory pain symptoms was confirmed. Another important finding was that women with fibromyalgia and self-reported histories of physical or sexual abuse did not have increased levels of CRF in their CSF. This indicates that there may be subgroups of fibromyalgia patients with different neurobiological characteristics. Therefore, further studies are needed to better understand the association between CRF and pain symptoms in fibromyalgia ¹⁰⁵. In another study, the association between salivary cortisol levels and pain symptoms in patients with fibromyalgia was assessed at different times of day. The results obtained in this study revealed a strong relationship between salivary cortisol and pain symptoms only at the time of awakening and the 1 h that followed in women with fibromyalgia. Furthermore, no relationship was observed between the cortisol level and symptoms of fatigue or stress. These findings suggest that early-day pain symptoms are associated with changes in hypothalamic–pituitary–adrenal axis (HPA) function in women with fibromyalgia.

However, to date, the results regarding the involvement of the hypothalamic–pituitary–adrenal axis (HPA) in the pathophysiology of fibromyalgia have been conflicting, and new studies will be needed in the future to fully clarify this aspect ¹⁰⁰. Furthermore, there are indications that total and free cortisol levels are dissociated in fibromyalgia patients. They have normal salivary and free plasma cortisol despite having reduced total cortisol levels. A possible explanation for this finding is a reduced concentration of glucocorticoid-binding globulin (CBG). Reduced levels of glucocorticoid-binding globulin have been reported in fibromyalgia patients compared to healthy patients. It is of particular interest that chronic social stress can lead to reduced levels of glucocorticoid-binding globulin, while IL-6 and IL-1β, which can also inhibit glucocorticoid-binding globulin production, may contribute further ¹⁰⁶.

The possible pathogenetic role of the growth hormone (GH)/insulin-like growth factor 1 (IGF-1) axis was also investigated. Several studies have found that about one-third of individuals with fibromyalgia have lower IGF-1 levels than control groups ¹⁰⁷. Serial measurements at 12 to 24 h also showed a reduction in growth hormone (GH) secretion in patients with fibromyalgia, particularly at night. Since GH secretion occurs mainly during phase 3 of sleep and 80% of patients have sleep disturbances, it remains to be clarified whether the nature of this alteration is primary or secondary ¹⁰⁸. Given the higher prevalence of fibromyalgia in the female population, the role of estrogens in this pathology was investigated. However, the results of various studies suggest that this role is limited, and the only significant result is an increased serum concentration of the G protein-coupled estrogen receptor (GPER) in patients with fibromyalgia compared to healthy subjects ¹⁰⁹. Although a strong correlation with the disease allows us to hypothesize the possible use of this receptor as a potential diagnostic biomarker, the exact mechanism by which it fits into the pathophysiological cascade remains unclear ¹¹⁰.

Psychopathological factors

Psychiatric comorbidities in fibromyalgia constitute a relevant aspect of the disease, and a close correlation between stress and fibromyalgia symptoms has been described several times. According to several studies, the prevalence of psychiatric comorbidities, such as anxiety disorders and depression, among patients with this pathology reaches 60% in certain subpopulations ¹¹¹. The presence of depressive patterns has been shown to correlate with a worse prognosis: patients with comorbid symptoms of depression seem to report pain of greater severity and duration as well as a greater degree of hyperalgesia/allodynia than healthy controls. Furthermore, these psychiatric aspects seem to have a certain predictive value in relation to various somatic symptoms, including musculoskeletal pain and headaches ¹¹². The impact of depression symptoms on pain processing is still unclear. A study in fibromyalgia patients attempted to evaluate this correlation by comparing the results of quantitative sensory tests and neuronal responses to pressure stimuli (assessed by functional magnetic resonance imaging (fMRI)) with the levels of symptoms of depression. The results showed that the symptom levels of depression were not associated with quantitative test results or with the extent of neuronal activation in brain areas, such as primary and secondary somatosensory cortices, that are associated with the sensory dimension of pain. However, symptoms of depression were observed to be associated with the extent of pain-evoked neuronal activation in the amygdala and contralateral anterior insula, which are brain areas associated with affective pain processing. Therefore, these findings suggest the existence of parallel, possibly independent, neuronal pain processing networks for sensory and affective pain elements ¹¹³.

The therapeutic aspect is an element that supports the pathogenetic overlap between depressive disorder and fibromyalgia. The effectiveness of treatment with antidepressant drugs (e.g., serotonin-norepinephrine reuptake inhibitors (SNRIs) and tricyclics) has in fact been described by numerous studies on fibromyalgia patients and constitutes one of the main therapeutic strategies in both fibromyalgia and other chronic pain conditions, such as chronic headache and irritable bowel (IBS), which are often symptoms of fibromyalgia ¹¹⁴, ¹¹⁵, ¹¹⁶. The effectiveness of serotonin-norepinephrine reuptake inhibitors (SNRIs) and other double-acting antidepressants, such as mirtazapine, suggests that neurotransmission dysfunction of both serotonin and norepinephrine exists in fibromyalgia ¹¹⁷. Similar to observations for the depressive pattern, stress also appears to be both a predictive and negative prognostic factor. It has been shown that stress can modulate pain sensitivity by inducing hyperalgesia or allodynia through alterations in the physiological circadian secretion of cholesterol, therefore indirectly inducing the release of pro-inflammatory cytokines and setting in motion the pathophysiological processes described above ¹¹⁸, ¹¹⁹, ¹²⁰.

Animal studies have shown that stress induction (e.g., swimming stress and cold stress) can produce muscle and skin hyperalgesia that lasts for weeks after the stressor ¹²¹, ¹²², ¹²³. On the other hand, milder stressors (e.g., fatigue and acoustic stress), which do not produce hyperalgesia on their own, can cause an increase in and prolongation of the hyperalgesic response to a subthreshold or mild noxious stimulus ¹²⁴, ¹²⁵, ¹²⁶. Other studies have shown that animals exposed to stressors also exhibit changes in the spinal cord. In particular, animals showed a greater expression of c-fos in response to formalin, as well as a reduction in the basal and induced release of the inhibitory neurotransmitter GABA; a reduction in mu-opioid agonist antinociception enhanced the basal and evoked the release of glutamate ¹²⁷, ¹²⁸, suggesting both increased central excitability and reduced central inhibition. In animals, stress-induced hyperalgesia was reduced by the spinal blockade of substance P, calcitonin gene-related peptide (CGRP), NMDA-glutamate receptors and neurokinin-1 receptors, all substances involved in the neurotransmission of pain ¹²⁶. At the supraspinal level, cold stress-induced alterations were observed in the serotonergic system, with reductions in both serotonin (5-HT) and 5-hydroxy indoleacetic acid (5-HIAA) levels in the supraspinal regions ¹²⁹. Therefore, stress and psychological factors are involved in the development and severity of fibromyalgia.

Poor Sleep

Sleep disorders are classically described within the symptomatic process of fibromyalgia. However, some recently reported data have generated the hypothesis that sleep disorders may be included among the causative factors of this pathology, rather than among its manifestations. Studies published in recent years have described a bidirectional correlation between sleep disturbances and widespread musculoskeletal pain, and it even seems that insomnia tends to precede the onset of pain and has predictive value regarding its onset and its persistence ¹³⁰, ¹³¹. Studies carried out in healthy subjects also seem to show that total, partial and stage-specific sleep deprivation leads to hyperalgesia, an increased incidence of spontaneous pain and mood alterations, particularly anxiety and depression ¹³², ¹³³. In a further study by Smith et al. ¹³⁴, the authors hypothesized that the development or aggravation of somatic and psychiatric symptoms is secondary to sleep discontinuity rather than sleep deprivation. In addition to the number of awakenings, the cyclic alternating pattern (CAP) is a useful tool to analyze this discontinuity. It is represented by short cycles of periodic electroencephalographic activity of non-REM sleep, distinct from the background rhythm and with a periodicity of up to one minute ¹³⁵. The cyclic alternating pattern (CAP) has been shown to be frequent in fibromyalgia patients and correlated with poor quality of sleep and with the severity of pain observed in these patients ¹³⁶.

Findings in human studies carried out through the application of evoked potentials indicate that increased nociceptive sensitivity in response to sleep deprivation could derive from dysregulation of the descending pathways of pain control or from cognitive amplification of the central origin, thus excluding the mechanism of sensory amplification ¹³⁷. Biochemical analyses suggest that an insufficient amount of sleep could also play a facilitating role in nociception through the elevation of the serum concentration of IL-6, thus entering the pathogenetic cascade with an inflammatory substrate ¹³². The structural analysis of sleep obtained by EEG studies provides additional support for the hypothesis that sleep alterations are among the causative factors of fibromyalgia. One of the first works on this aspect was a study by Moldofsky et al. ¹³⁸, in which microstructural analysis identified the presence of a rhythm component typical of wakefulness within the non-REM sleep pattern, particularly during periods of slow delta rhythm (0.5 to 2 Hz, characteristic of deep sleep), among both fibromyalgia patients and healthy subjects deprived of the deeper stages of alpha sleep (8 to 13 Hz). Moreover, in healthy subjects, deprivation was accompanied by a set of musculoskeletal and psychological symptoms similar to those chronically reported by patients. In light of these data, a hypothesis was put forward that considered fibromyalgia, then called fibrositis, to be a “non-restorative sleep syndrome”, in which an arousal mechanism (presumably responsible for the alpha component) interferes with non-REM sleep and its restorative function, consequently generating mood alterations and characteristic somatic disturbances. More recent human studies have described the mechanisms underlying alpha-delta sleep (ADS, the intrusion of alpha rhythms in the deep phases of sleep), highlighting the role played by the thalamus, which, in turn, is modulated by GABAergic and cholinergic afferents ¹³⁹, ¹⁴⁰. It has been observed that the alpha-delta sleep (ADS, the intrusion of alpha rhythms in the deep phases of sleep) phenomenon manifests itself in three different patterns: phasic (contemporary with delta activity), tonic (continuous throughout NREM sleep) and low alpha activity. Among these, the phasic pattern appears to be the most common among fibromyalgia patients and is the one that correlates most strongly with symptoms such as insomnia and pain ¹⁴¹.

It should be noted, however, that alpha-delta sleep is not an exclusive feature of fibromyalgia: it is also seen in a number of chronic pain syndromes and in some healthy individuals. Unlike alpha activity, the functional anatomical substrate of sleep spindles has been extensively studied. These are trains of electroencephalographic waves with a frequency between 12 and 16 Hz, lasting between 0.5 and 1.5 s and recurring every 3 to 10 s, and characteristic of non-REM (NREM) sleep, particularly the N2 stage of sleep (intermediate sleep). Sleep spindles are generated by the rhythmic firing of thalamic relay neurons, and their role is central in the induction and maintenance of NREM sleep, as well as in the gating mechanism through which transmission and the consequent cortical response to both internal and external stimuli are attenuated during sleep (control of arousal status) ¹⁴², ¹⁴³, ¹⁴⁴, ¹⁴⁵. The frequency of spindles during NREM sleep is modulated by a series of factors, including age (inverse proportionality) and a certain degree of interindividual variability, as well as various pathological conditions in the neuropsychiatric field, such as depression, anxiety and stress ¹⁴⁶. A study by Landis et al. ¹⁴⁷ described a reduction in the frequency and amplitude of sleep spindles in a population of women with fibromyalgia compared to a control group, proposing the hypothesis of a dysfunction of the thalamo-cortical circuits underlying this alteration.

In a rat study ¹⁴⁸, a deep learning method, known as SpindleNet, was applied to characterize sleep spindle activity in animals with induced chronic pain. The results showed a correlation between a decrease in the frequency of spindles during NREM sleep and the level of chronic pain and allodynia, suggesting that this finding could be a biomarker of chronic pain as well as a target for neuromodulator therapy ¹⁴⁹. It is therefore possible to hypothesize that a dysfunctional primitive thalamus causes an alteration in its spindle pacemaker activity and alpha activity, compromising the restorative function of sleep and consequently generating the somatic and psychological symptoms of fibromyalgia, similar to what was suspected by Moldofsky et al ¹³⁸. In light of the important function of the thalamus in sensory transmission pathways, it can also be hypothesized that both sleep disturbances and hyperalgesia/allodynia are the direct result of thalamic alteration, representing independent manifestations of the same pathological process. The relationship between sleep disturbances and fibromyalgia has not yet been fully clarified, and new studies will be needed to better define the relationship between the two. At the moment, the main hypotheses converge in their proposal of a bidirectional correlation characterized by a positive feedback circuit.

Fibromyalgia diagnosis

If you think you have fibromyalgia, visit your doctor. Diagnosing fibromyalgia can be difficult, as there’s no specific test to diagnose the condition ¹⁵⁰.

The symptoms of fibromyalgia can vary and are similar to those of several other conditions.

During diagnosis, you’ll be asked about how your symptoms are affecting your daily life. If you have had any trouble sleeping or fatigue, tell your doctor how long you have had this problem. Your doctor may ask whether you have been feeling anxious or depressed since your symptoms began.

Your body will also be examined to check for visible signs of other conditions – for example, swollen joints may suggest arthritis, rather than fibromyalgia.

In the past, doctors would check 18 specific points on a person’s body to see how many of them were painful when pressed firmly. Newer 2016 guidelines from the American College of Rheumatology don’t require a tender point exam. Instead, the main factor needed for a fibromyalgia diagnosis is widespread pain throughout your body for at least three months ¹⁵¹.

Fibromyalgia may now be diagnosed in adults when all of the following criteria are met ¹⁵¹:

1. Generalized pain, defined as pain in at least 4 of 5 regions, is present.
2. Symptoms have been present at a similar level for at least 3 months.
3. Widespread pain index (WPI) ≥ 7 and symptom severity scale (SSS) score ≥ 5 OR WPI of 4–6 and SSS score ≥ 9.
4. A diagnosis of fibromyalgia is valid irrespective of other diagnoses. A diagnosis of fibromyalgia does not exclude the presence of other clinically important illnesses.

To meet the American College of Rheumatology 2016 criteria, you must have pain in at least four of these five areas:

• Left upper region, including shoulder, arm or jaw
• Right upper region, including shoulder, arm or jaw
• Left lower region, including hip, buttock or leg
• Right lower region, including hip, buttock or leg
• Axial region, which includes neck, back, chest or abdomen

Ruling out other conditions

If your doctor thinks you may have fibromyalgia, they’ll first have to rule out all other conditions that could be causing your symptoms. These conditions may include:

• chronic fatigue syndrome (also known as myalgic encephalomyelitis) – a condition that causes long-term tiredness
• rheumatoid arthritis – a condition that causes pain and swelling in the joints
• multiple sclerosis (MS) – a condition of the central nervous system (the brain and spinal cord) that affects movement and balance

Tests to check for some of these conditions include urine and blood tests, although you may also have X-rays and other scans.

Blood tests may include:

• Complete blood count
• Erythrocyte sedimentation rate
• Cyclic citrullinated peptide test
• Rheumatoid factor
• Thyroid function tests
• Anti-nuclear antibody
• Celiac serology
• Vitamin D

If there’s a chance that you may be suffering from sleep apnea, your doctor may recommend an overnight sleep study.

If you’re found to have another condition, you could still have fibromyalgia as well.

Criteria for diagnosing fibromyalgia

1990 American College of Rheumatology classification criteria was used in many clinical and therapeutic trials but has not been useful in diagnosing fibromyalgia in clinical practice.

The 1990 American College of Rheumatology fibromyalgia classification criteria included:

• Symptoms of widespread pain, present on both sides of the body and both above and below the waist
• Physical findings of at minimum 11 of 18 defined tender points:
  1. Suboccipital muscle insertion bilaterally
  2. Anterior aspect of C5 to C7 intertransverse spaces bilaterally
  3. Mid upper border of trapezius bilaterally
  4. Origin of supraspinatus muscle bilaterally
  5. Second costochondral junctions bilaterally
  6. 2cm distal to the lateral epicondyles bilaterally
  7. Upper outer quadrants of buttocks bilaterally
  8. Greater trochanteric prominence bilaterally
  9. Medial fat pad of the knees bilaterally

The pressure appropriate for detecting these tender points should be equal to 4 kg/cm², enough to whiten the nail bed of the fingertip of the examiner.

For the purposes of classification, the patient is said to have fibromyalgia if both criteria are met.

There were a number of limitations of the 1990 1990 American College of Rheumatology diagnostic criteria, which include the following:

• Physicians do not know how to examine tender points, perform the exam incorrectly, or refuse to do so.
• A number of symptoms that were previously not considered were increasingly appreciated as key symptoms of fibromyalgia.
• The criteria set the bar so high that it left little room for variation among fibromyalgia patients. Also, the patient whose symptoms improved failed to satisfy the 1990 criteria.

Criteria Needed for a Fibromyalgia Diagnosis (American College of Rheumatology Fibromyalgia Diagnostic Criteria 2010) ¹⁵²

1. Pain and symptoms over the past week, based on the total of number of painful areas out of 19 parts of the body plus level of severity of these symptoms:
   • a. Fatigue
   • b. Waking unrefreshed
   • c. Cognitive (memory or thought) problems
   • Plus number of other general physical symptoms
2. Symptoms lasting at least three months at a similar level
3. No other health problem that would explain the pain and other symptoms

Revised 2016 American College of Rheumatology guidelines don’t require a tender point exam. Instead, the main factor needed for a fibromyalgia diagnosis is widespread pain throughout your body for at least three months ¹⁵¹.

Fibromyalgia may now be diagnosed in adults when all of the following criteria are met ¹⁵¹:

1. Generalized pain, defined as pain in at least 4 of 5 regions, is present.
2. Symptoms have been present at a similar level for at least 3 months.
3. Widespread pain index (WPI) ≥ 7 and symptom severity scale (SSS) score ≥ 5 OR WPI of 4–6 and SSS score ≥ 9.
4. A diagnosis of fibromyalgia is valid irrespective of other diagnoses. A diagnosis of fibromyalgia does not exclude the presence of other clinically important illnesses.

Note:

• Widespread pain index (WPI): note the number of areas where and how many areas the patient has had pain in the prior week. The score will be between 0 and 19. Shoulder girdle, left hip (buttock, trochanter), left jaw, left upper back shoulder girdle, right hip (buttock, trochanter), right jaw, right lower back upper arm, left upper leg, left chest neck upper arm, right upper leg, right abdomen lower arm, left lower leg, left lower arm, right lower leg, right
• Symptom severity scale (SSS): Fatigue, waking unrefreshed, and cognitive symptoms. For each of the three symptoms above, indicate the severity level over the past week utilizing the following scale: 0 no problem; 1 slight or mild problems, generally mild or intermittent; 2 moderate, considerable problems, often present and/or at a moderate level; 3 severe: pervasive, continuous, life-disturbing problems. Considering somatic symptoms in general, indicate whether the patient has: 0 for no symptoms, 1 for a few symptoms, 2 for a moderate number of symptoms, and 3 for many symptoms. The symptom severity scale (SSS) sums the severity of the 3 symptoms (fatigue, waking unrefreshed, cognitive symptoms) plus the severity) of general somatic symptoms. The final score is between 0 and 12.

To meet the American College of Rheumatology 2016 criteria, you must have pain in at least four of these five areas:

• Left upper region, including shoulder, arm or jaw
• Right upper region, including shoulder, arm or jaw
• Left lower region, including hip, buttock or leg
• Right lower region, including hip, buttock or leg
• Axial region, which includes neck, back, chest or abdomen

Diagnosing other conditions

It’s also possible to have other conditions alongside your fibromyalgia, such as:

• depression
• anxiety
• irritable bowel syndrome (IBS)

If your symptoms suggest that you have another condition as well as fibromyalgia, you may need further tests to diagnose these. Identifying all possible conditions will help to guide your treatment.

Fibromyalgia test

Fibromyalgia is usually diagnosed by documenting the patient’s medical history, ruling out disorders and diseases that may be mimicking or exacerbating fibromyalgia, and by utilizing the criteria last updated by the American College of Rheumatology in 2016 ¹⁵, ³, ¹⁵¹, ²³.

Revised American College of Rheumatology 2016 guidelines don’t require a tender point exam. Instead, the main factor needed for a fibromyalgia diagnosis is widespread pain throughout your body for at least three months ¹⁵¹.

Fibromyalgia may now be diagnosed in adults when all of the following criteria are met ¹⁵¹:

1. Generalized pain, defined as pain in at least 4 of 5 regions, is present.
2. Symptoms have been present at a similar level for at least 3 months.
3. Widespread pain index (WPI) ≥ 7 and symptom severity scale (SSS) score ≥ 5 OR WPI of 4–6 and SSS score ≥ 9.
4. A diagnosis of fibromyalgia is valid irrespective of other diagnoses. A diagnosis of fibromyalgia does not exclude the presence of other clinically important illnesses.

To meet the American College of Rheumatology 2016 criteria, you must have pain in at least four of these five areas ¹⁵¹:

• Left upper region, including shoulder, arm or jaw
• Right upper region, including shoulder, arm or jaw
• Left lower region, including hip, buttock or leg
• Right lower region, including hip, buttock or leg
• Axial region, which includes neck, back, chest or abdomen.

Figure 2. Fibromyalgia diagnostic criteria

2016 Revisions to the 2010/2011 Fibromyalgia Diagnostic Criteria

A limitation of the widespread pain index (WPI) is the fact that it counts the number of painful areas without considering their distribution in the body. Patients with regional pain disorders can fulfill the 2010 American College of Rheumatology preliminary diagnostic criteria since pain can be located in 3 or more areas in the same region ¹⁵³. To overcome this issue the 2016 revision of the diagnostic criteria require the pain to be generalized (multisite pain). The areas widespread pain index (WPI) assesses are divided in 5 regions (Table 2) and the diagnosis of fibromyalgia requires the distribution of pain in 4 out of 5 regions ¹⁵⁴. The jaw, the chest and the abdomen area are problematic when they are used to define a region. In this way they are excluded from the definition of generalized pain ¹⁵⁵. Since pain needs to be located in at least 4 areas according to the 2016 revision, the previous criterion for diagnosis, widespread pain index (WPI) of 3-6 and symptom severity (SS) scale score ≥9 was changed to widespread pain index (WPI) of 4-6 and symptom severity (SS) scale score ≥9.

The 2010 and 2011 criteria are extremely similar. Their difference is that the 2010 criteria are physician-based and can be used in clinical practice for the diagnosis of fibromyalgia, while the 2011 criteria are self-reported and can be used only in survey research. According to the 2010 criteria the symptom severity (SS) scale assesses a wide range of somatic symptoms, which makes them impractical for use in questionnaires. With the 2016 revision the assessment of somatic symptoms that is included in the symptom severity (SS) scale is limited to headaches, pain and cramps in the lower abdomen and depression. In this way, there is no longer need for different criteria for clinical practice and for survey research. The same criteria can be used in both settings having 2 different methods of administration.

One prerequisite for diagnosis of fibromyalgia according to the 2010 American College of Rheumatology preliminary diagnostic criteria is the patient not to have a condition that would otherwise explain the pain. The authors of these criteria clarified that this does not mean that the diagnosis of fibromyalgia is an exclusion diagnosis. However, this phrasing was not considered clear enough and caused significant misunderstanding. In this way this criterion was removed in the 2016 revision. The diagnosis of fibromyalgia can be valid even if there is another condition that can cause the pain that is attributed to fibromyalgia. According to this definition fibromyalgia can coexist with other clinically significant conditions that can cause pain.

Table 2. 2016 Fibromyalgia Diagnostic Criteria

AAPT Diagnostic Criteria

In an attempt to improve the recognition of fibromyalgia in clinical practice, the ACTTION-APS Pain Taxonomy (AAPT) fibromyalgia working group proposed new diagnostic criteria in 2018 ¹⁵⁶. These criteria are similar to the American College of Rheumatology criteria as they require the pain to be generalized (multisite), require the presence of non-pain symptoms and require the symptoms to be present for at least 3 months. These diagnostic criteria are more simple than the American College of Rheumatology criteria and they can be easily implemented in primary clinical practice, but some of their aspects have been criticized ¹⁵⁷. According to the AAPT criteria the head, the abdomen and the chest are included in the areas that are assessed for the presence of generalized musculoskeletal pain. However, these regions are problematic since pain originating from the teeth, the heart and the bowel can be referred to these areas. Additionally, the AAPT criteria do not have the ability to quantify the severity of fibromyalgia as, apart from the generalized pain, they only assess the presence or absence of the 2 most common non-pain symptoms of fibromyalgia, abolishing all other somatic symptoms.

ACTTION-APS Pain Taxonomy (AAPT) Diagnostic Criteria ¹⁵⁸ 

• Multisite pain defined as 6 or more pain sites from a total of 9 possible sites:
  • Head
  • Left arm
  • Right arm
  • Chest
  • Abdomen
  • Upper back and spine
  • Lower back and spine, including buttocks
  • Left leg
  • Right leg
• Moderate to severe sleep problems or fatigue
• Multisite pain plus fatigue or sleep problems must have been present for at least 3 months

NOTE. The presence of another pain disorder or related symptoms does not rule out a diagnosis of fibromyalgia. However, a clinical assessment is recommended to evaluate for any condition that could fully account for the patient’s symptoms or contribute to the severity of the symptoms.

Diagnosing other conditions

It’s also possible to have other conditions alongside your fibromyalgia, such as:

• depression
• anxiety
• irritable bowel syndrome (IBS)

If your symptoms suggest that you have another condition as well as fibromyalgia, you may need further tests to diagnose these. Identifying all possible conditions will help to guide your treatment.

Laboratory Tests

Laboratory tests can be useful to help diagnose conditions with symptoms similar to fibromyalgia, such as rheumatoid arthritis, Sjögren syndrome, thyroid disease, and lupus. It is not usually cost effective or necessary to do extensive screening. General tests that may be ordered include:

• Comprehensive metabolic panel – to examine electrolytes, proteins, liver and kidney function, calcium, and glucose
• CBC (complete blood count) – to look for anemia, a possible cause of weakness and fatigue
• TSH (thyroid stimulating hormone) and/or other thyroid testing since hypothyroidism can cause symptoms similar to fibromyalgia
• ANA (anti-nuclear antibody) – to rule out autoimmune disorders, such as lupus or Sjogren syndrome
• CK (creatine kinase) – to rule out other conditions that can cause muscle weakness or pain
• Erythrocyte sedimentation rate (ESR)
• Cyclic citrullinated peptide test
• Rheumatoid factor
• Celiac serology
• Vitamin D

A healthcare practitioner will typically consider the following in developing a diagnosis: results of the general tests, the patient’s history (including family history and risk factors for certain diseases), and results of the physical examination. Based on these findings, some additional tests could be done.

Meanwhile, researchers continue to look for new testing protocols that may be more specific for fibromyalgia.

Non-Laboratory Tests

Electromyography (EMG) may be performed to assess the health of muscles and the nerves that control them. Occasionally, an imaging scan such as an MRI (magnetic resonance imaging) may be ordered to help rule out the possibility of multiple sclerosis or other diseases that may cause symptoms similar to fibromyalgia.

Fibromyalgia treatment

Your doctor may recommend treating your symptoms with acetaminophen (paracetamol) first. He or she may also recommend an anti-depressant, such as duloxetine or milnacipran. Anti-seizure medicines, such as preglabin, may also be effective in managing your pain. Nonsteroidal anti-inflammatory medicines (which include ibuprofen, aspirin, and naproxen) are not usually effective in treating fibromyalgia when taken alone.

Making changes in your lifestyle and daily habits can help you feel better. Remember, your treatment won’t be as effective if you don’t take an active role in your health care. The following are some ways you can take an active role in managing your fibromyalgia symptoms.

Join a self-management education class, which helps people with arthritis or other conditions—including fibromyalgia—be more confident in how to control their symptoms, how to live well and understand how the condition affects their lives. You can find more info on Self-Management Resource Center here: https://www.selfmanagementresource.com/

Chronic Disease Self-Management Program is an effective self-management education workshop for people with chronic health problems. The program specifically addresses arthritis, diabetes, lung and heart disease, but teaches skills useful for managing a variety of chronic diseases. This program was developed at Stanford University. Locate a Chronic Disease Self-Management Program in your area here: http://www.eblcprograms.org/evidence-based/map-of-programs/

Self-help

If you have fibromyalgia, there are several ways to change your lifestyle to help relieve your symptoms and make your condition easier to live with.

Your doctor, or another healthcare professional treating you, can offer advice and support about making these changes part of your everyday life.

There are organizations to support people with fibromyalgia that may also be able to offer advice.

• Self-Management Resource Center: https://www.selfmanagementresource.com/
• Chronic Disease Self-Management Program in your area here: http://www.eblcprograms.org/evidence-based/map-of-programs/
• UK Fibromyalgia’s support group: http://ukfibromyalgia.com/index.php
• Fibromyalgia Action UK: https://healthunlocked.com/fibromyalgia-action-uk

Below are some tips that may help relieve symptoms of fibromyalgia. You can also read more information about living with pain.

Exercise

One of the best things you can do if you have fibromyalgia is engage in moderate exercise on a regular basis. Exercise can reduce your pain, give you more energy, reduce stress, and help you sleep better. If you’re not used to exercising, be sure to talk to your doctor before you start. If you have a physical therapist on your health care team, he or she can help you develop an exercise routine that’s right for you. It’s usually best to start with low-impact aerobic exercise (for example, walking or water aerobics) for a short period of time a few days a week. As your pain decreases and your energy increases, you can gradually increase the intensity and frequency of your exercise.

Aerobic exercise

Aerobic activities are any kind of rhythmic, moderate-intensity exercises that increase your heart rate and make you breathe harder. Examples include:

• walking
• cycling
• swimming

Research suggests that aerobic fitness exercises should be included in your personalised exercise plan, even if you can’t complete these at a high level of intensity. For example, if you find jogging too difficult, you could try brisk walking instead.

A review of a number of studies found that aerobic exercises may improve quality of life and relieve pain. As aerobic exercises increase your endurance (how long you can keep going), these may also help you function better on a day-to-day basis.

Resistance and strengthening exercises

Resistance and strengthening exercises are those that focus on strength training, such as lifting weights. These exercises need to be planned as part of a personalised exercise programme; if they aren’t, muscle stiffness and soreness could be made worse.

A review of a number of studies concluded that strengthening exercises may improve:

• muscle strength
• physical disability
• depression
• quality of life

People with fibromyalgia who completed the strengthening exercises in these studies said they felt less tired, could function better and experienced a boost in mood.

Improving the strength of your major muscle groups can make it easier to do aerobic exercises.

Pacing yourself

If you have fibromyalgia, it’s important to pace yourself. This means balancing periods of activity with periods of rest, and not overdoing it or pushing yourself beyond your limits.

If you don’t pace yourself, it could slow down your progress in the long term. Over time, you can gradually increase your periods of activity, while making sure they’re balanced with periods of rest.

If you have fibromyalgia, you will probably have some days when your symptoms are better than others. Try to maintain a steady level of activity without overdoing it, but listen to your body and rest whenever you need to.

Avoid any exercise or activity that pushes you too hard, because this can make your symptoms worse. If you pace your activities at a level that’s right for you, rather than trying to do as much as possible in a short space of time, you should make steady progress.

For example, it may help to start with gentler forms of exercise – such as tai chi, yoga and pilates – before attempting more strenuous aerobic or strengthening exercises.

Recognize stress and take steps to reduce it

Because stress makes the symptoms of fibromyalgia worse, it’s important to recognize when you’re feeling stressed. Signs of stress may include a feeling of tension in your shoulders or neck, an upset stomach, or a headache. Unfortunately, there isn’t a way to completely get rid of stress in your life. However, you can focus on changing the way you react to stress. For example, you might set aside time each day to practice deep-breathing techniques or meditation.

Relaxation

If you have fibromyalgia, it’s important to regularly take time to relax or practice relaxation techniques. Stress can make your symptoms worse or cause them to flare up more often. It could also increase your chances of developing depression.

There are many relaxation aids available, including books, tapes and courses, although deep-breathing techniques or meditation may be just as effective. Try to find time each day to do something that relaxes you. Taking time to relax before bed may also help you sleep better at night.

Talking therapies, such as counseling, can also be helpful in combating stress and learning to deal with it effectively. Your GP may recommend you try this as part of your treatment.

Establish healthy sleep habits

Lack of sleep can make your fibromyalgia symptoms worse. And increased pain makes it hard to get restful sleep. To avoid getting caught in this cycle, try to have healthy sleeping habits. Avoid caffeine and alcohol before bedtime, go to bed and wake up at the same time each day (including weekends), and limit naps during the day.

Fibromyalgia can make it difficult to fall asleep or stay asleep (known as insomnia). If you have problems sleeping, it may help to:

• get up at the same time every morning
• try to relax at least 1 hour before going to bed
• try to create a bedtime routine, such as taking a bath and drinking a warm, milky drink every night
• avoid caffeine, nicotine and alcohol before going to bed
• avoid eating a heavy meal late at night
• make sure your bedroom is a comfortable temperature, and is quiet and dark – use thick curtains, blinds, an eye mask or ear plugs
• exercise regularly during the day
  make sure your mattress, pillows and covers are comfortable
• avoid checking the time throughout the night

Everyone needs different amounts of sleep. On average we need:

• Adults – 7 to 9 hours
• Children – 9 to 13 hours
• Toddlers and babies – 12 to 17 hours

You probably don’t get enough sleep if you’re constantly tired during the day.

Get into a routine

Many people who have fibromyalgia do better when their schedule follows a routine pattern. This usually means that each day they have meals at the same times, go to bed and get up at the same times, and exercise at the same time. Try to keep your weekend and holiday schedules as similar to your weekday schedule as possible.

Make healthy lifestyle choices

By making healthy choices, you’ll have more energy, you’ll feel better, and you’ll lower your risk for other health problems. Eat a healthy, balanced diet. Limit the amount of alcohol you drink. If you use tobacco products, stop. Lose weight if you are overweight.

Cognitive-behavioral therapy

Cognitive-behavioral therapy (CBT) has been proven effective for managing fibromyalgia symptoms. One of the goals of the fibromyalgia treatment should be to help patients understand the effect of thoughts, beliefs and expectations on their symptoms. With the help of a trained mental health counselor, a person learns how to change negative thought patterns and behaviors to relieve pain, promote better sleep and improve functioning. This can help them to abolish the perception of helplessness and the catastrophizing thoughts that can adversely influence their condition. Patients with greater self-efficacy are more likely to have a good response to treatment programs and experience better outcomes. The beneficial effect of cognitive-behavioral therapies in fibromyalgia patients with anxiety and depression disorders is limited to a reduction of negative mood, while the rest of the patients also demonstrate a reduction of pain and fatigue. It is worth mentioning that psychologically based interventions, have been proven to be useful when they are compared to no treatment or treatment other than aerobic exercise ¹⁵⁹. Preliminary data from functional MRI studies suggest that cognitive-behavioral therapies have the ability to restore the alterations in the functional connectivity of brain areas responsible for pain processing observed in fibromyalgia patients ¹⁶⁰.

Medications

People with fibromyalgia are typically treated with pain medicines, antidepressants, muscle relaxants, and sleep medicines. You may need to take several different types of medicines for fibromyalgia, including painkillers and antidepressants. These are described below.

The U.S. Food and Drug Administration (FDA) has approved three drugs for the treatment of fibromyalgia. In June 2007, Lyrica (pregabalin) became the first FDA-approved drug for specifically treating fibromyalgia; a year later, in June 2008, Cymbalta (duloxetine hydrochloride) became the second; and in January 2009, Savella (milnacipran HCI) became the third ¹⁶¹. Older drugs that affect these same brain chemicals also may be used to treat fibromyalgia. These include amitriptyline (Elavil) and cyclobenzaprine (Flexeril). Other antidepressant drugs can be helpful in some patients. Side effects vary by the drug. Ask your doctor about the risks and benefits of your medicine.

Lyrica, Cymbalta and Savella reduce pain and improve function in some people with fibromyalgia. While those with fibromyalgia have been shown to experience pain differently from other people, the mechanism by which these drugs produce their effects is unknown. There is data suggesting that these drugs affect the release of neurotransmitters in the brain. Neurotransmitters are chemicals that transmit signals from one neuron to another. Treatment with Lyrica, Cymbalta, and Savella may reduce the level of pain experienced by some people with fibromyalgia.

Lyrica, marketed by Pfizer Inc., was previously approved to treat seizures, as well as pain from damaged nerves that can happen in people with diabetes (diabetic peripheral neuropathy) and in those who develop pain following the rash of shingles. Side effects of Lyrica including sleepiness, dizziness, blurry vision, weight gain, trouble concentrating, swelling of the hands and feet, and dry mouth. Allergic reactions, although rare, can occur.

Cymbalta, marketed by Eli Lilly and Co., was previously approved to treat depression, anxiety, and diabetic peripheral neuropathy. Cymbalta’s side effects include nausea, dry mouth, sleepiness, constipation, decreased appetite, and increased sweating. Like some other antidepressants, Cymbalta may increase the risk of suicidal thinking and behavior in people who take the drug for depression. Some people with fibromyalgia also experience depression.

Savella, marketed by Forest Pharmaceuticals, Inc., is the first drug introduced primarily for treating fibromyalgia. Savella is not used to treat depression in the United States, but acts like medicines that are used to treat depression (antidepressants) and other mental disorders. Antidepressants may increase suicidal thoughts or actions in some people. Side effects include nausea, constipation, dizziness, insomnia, excessive sweating, vomiting, palpitations or increased heart rate, dry mouth and high blood pressure.

Studies of both drugs showed that a substantial number of people with fibromyalgia received good pain relief, but there were others who didn’t benefit.

Lyrica and Cymbalta are approved for use in adults 18 years and older ¹⁶¹. The drug manufacturers have agreed to study their drugs in children with fibromyalgia and in breastfeeding women.

Painkillers

Simple painkillers that are available over the counter from a pharmacy, such as paracetamol, can sometimes help relieve the pain associated with fibromyalgia. However, these aren’t suitable for everyone, so make sure you read the manufacturer’s instructions that come with the medication before using them.

If over-the-counter painkillers aren’t effective, your doctor (or another healthcare professional treating you) may prescribe a stronger painkiller, such as codeine or tramadol.

However, these painkillers can be addictive and their effect tends to weaken over time. This means that your dose may need to be gradually increased and you could experience withdrawal symptoms if you stop taking them. Other side effects include diarrhea and fatigue (extreme tiredness).

Antidepressants

Antidepressant medication can also help to relieve pain for some people with fibromyalgia. They boost the levels of certain chemicals that carry messages to and from the brain, known as neurotransmitters.

Low levels of neurotransmitters may be a factor in fibromyalgia, and it’s believed that increasing their levels may ease the widespread pain associated with the condition.

There are different types of antidepressants. The choice of medicine largely depends on the severity of your symptoms and any side effects the medicine may cause.

Antidepressants used to treat fibromyalgia include:

• tricyclic antidepressants – such as amitriptyline
• serotonin-noradrenaline reuptake inhibitors (SNRIs) – such as duloxetine and venlafaxine
• selective serotonin reuptake inhibitors (SSRIs) – such as fluoxetine and paroxetine

A medication called pramipexole, which isn’t an antidepressant, but also affects the levels of neurotransmitters, is sometimes used as well.

Antidepressants can cause a number of side effects, including:

• feeling sick
• dry mouth
• drowsiness
• feeling agitated, shaky or anxious
• dizziness
• weight gain
• constipation

For information on the side effects of your particular medication, check the patient information leaflet that comes with it.

Medication to help you sleep

As fibromyalgia can affect your sleeping patterns, you may want medicine to help you sleep. If you’re sleeping better, you may find that other symptoms aren’t as severe.

For sleep problems, some of the medicines that treat pain also improve sleep. These include cyclobenzaprine (Flexeril), amitriptyline (Elavil), gabapentin (Neurontin) or pregabalin (Lyrica). It is not recommended that patients with fibromyalgia take sleeping medicines like zolpidem (Ambien) or benzodiazepine medications.

Speak to your doctor if you think you could benefit from a medicine like this. They may recommend an over-the-counter remedy, or prescribe a short course of a stronger medication. Some antidepressants may also improve your sleep quality.

Muscle relaxants

If you have muscle stiffness or spasms (when the muscles contract painfully) as a result of fibromyalgia, your doctor may prescribe a short course of a muscle relaxant, such as diazepam.

These medicines may also help you sleep better because they can have a sedative (sleep-inducing) effect.

Anticonvulsants (anti-seizure medicine)

You may also be prescribed an anticonvulsant (anti-seizure) medicine, as these can be effective for those with fibromyalgia.

The most commonly used anticonvulsants for fibromyalgia are pregabalin and gabapentin. These are normally used to treat epilepsy, but research has shown they can improve the pain associated with fibromyalgia in some people.

Some common side effects of pregablin and gabapentin include:

• dizziness
• drowsiness
• swelling of your hands and feet (edema)
• weight gain

Antipsychotics

Antipsychotic medicines, also called neuroleptics, are sometimes used to help relieve long-term pain. Studies have shown that these medications may help conditions such as fibromyalgia, but further research is needed to confirm this.

Possible side effects include:

• drowsiness
• tremors (shaking)
• restlessness

Other treatment options

As well as medication, there are other treatment options that can be used to help cope with the pain of fibromyalgia, such as:

• swimming, sitting or exercising in a heated pool or warm water (known as hydrotherapy or balneotherapy)
• an individually tailored exercise programme
• cognitive behavioral therapy (CBT) – a talking therapy that aims to change the way you think about things, so you can tackle problems more positively
• psychotherapy – a talking therapy that helps you understand and deal with your thoughts and feelings
• relaxation techniques
• psychological support – any kind of counseling or support group that helps you deal with issues caused by fibromyalgia

See self-help for fibromyalgia for more information about exercise and relaxation techniques.

Alternative therapies

A variety of different therapies can help reduce the effect that fibromyalgia has on your body and your life. Some people with fibromyalgia try complementary or alternative treatments, such as:

• Acupuncture. Acupuncture involves the insertion of very thin needles through your skin at strategic points on your body. A key component of traditional Chinese medicine, acupuncture is most commonly used to treat pain. Increasingly, it is being used for overall wellness, including stress management. Some studies indicate that acupuncture helps relieve fibromyalgia symptoms, while others show no benefit.
• Massage therapy. In massage therapy, a massage therapist rubs and kneads the soft tissues of your body. The soft tissues include muscle, connective tissue, tendons, ligaments and skin. The massage therapist varies the amount of pressure and movement. Massage can reduce your heart rate, relax your muscles, improve range of motion in your joints and increase production of your body’s natural painkillers. It often helps relieve stress and anxiety.
• Chiropractic adjustment. Chiropractic adjustment is a procedure in which trained specialists (chiropractors) use their hands or a small instrument to apply a controlled, sudden force to a spinal joint. The goal of this procedure, also known as spinal manipulation, is to improve spinal motion and improve your body’s physical function.
• Yoga and tai chi. These practices combine meditation, slow movements, deep breathing and relaxation. Both have been found to be helpful in controlling fibromyalgia symptoms.
• Aromatherapy. Aromatherapy or the therapeutic use of essential oils extracted from plants. Aromatherapy is thought to work by stimulating smell receptors in your nose, which then send messages through your nervous system to the limbic system — the part of your brain that controls emotions. Aromatherapy might have health benefits, including:
  • Relief from anxiety and depression.
  • Improved quality of life, particularly for people with chronic health conditions.
• Physical therapy. A physical therapist can teach you exercises that will improve your strength, flexibility and stamina. Water-based exercises might be particularly helpful.
• Occupational therapy. An occupational therapist can help you make adjustments to your work area or the way you perform certain tasks that will cause less stress on your body.
• Counseling. Talking with a counselor can help strengthen your belief in your abilities and teach you strategies for dealing with stressful situations.

There’s little scientific evidence that such treatments help in the long term. However, some people find that certain treatments help them to relax and feel less stressed, allowing them to cope with their condition better.

Research into some complementary medicines, such as plant extracts, has found they’re not effective in treating fibromyalgia. If you decide to use any complementary or herbal remedies, check with your doctor first. Some remedies can react unpredictably with other medication, or make it less effective.

Treating other conditions

If you’ve been diagnosed with fibromyalgia and another condition, such as depression or irritable bowel syndrome (IBS), you may need to have separate treatment for these. For example, additional counseling or medication may be recommended.

Fibromyalgia diet

Some people say their fibromyalgia symptoms are worsened by certain foods or food additives — such as refined flour, dairy products, sugar, sugar substitutes or MSG — but there’s no clear research-based evidence to support this. Fibromyalgia patients produce higher levels of harmful free radicals than healthy people and have a decreased antioxidant ability, contributing to oxidative stress ¹⁶².

Some studies show a benefit in avoiding certain foods or additives, while other studies don’t show such a correlation. Scientists are investigating possible connections between the consumption of gluten and fibromyalgia symptoms, but more research is needed.

People who have fibromyalgia are also more likely to be overweight or obese, and both problems impact quality of life. For some people, losing weight can help reduce fibromyalgia symptoms.

The progression of fibromyalgia may be dependent on increased reactive oxygen species (ROS). Reactive oxygen species (ROS) are highly reactive chemicals, containing oxygen, that react easily with other molecules, resulting in potentially damaging modifications. Treatment with antioxidants and vitamins, in addition to antidepressants and structural analogs of gamma-aminobutyric acid (GABA), was able to change the symptoms of fibromyalgia patients ¹⁶³. Certain groups of bioactive compounds derived from medicinal plants have also demonstrated analgesic activity and antioxidant properties with respect to fibromyalgia: these include essential oils ¹⁶⁴, extracts ¹⁶⁵, monoterpenes ¹⁶⁶, sesquiterpenes ¹⁶⁷ and alkaloids ¹⁶⁸.

Table 3. Compounds with antioxidant and analgesic properties for fibromyalgia management

Fibromyalgia Prognosis

Most longitudinal long-term studies have shown that most fibromyalgia patients continue to have chronic pain and fatigue, but the majority of these studies have been from tertiary referral centers ¹⁷. In contrast, patients treated by primary care physicians in the community have a much better prognosis ¹⁷. Many demographic and psychosocial factors significantly impact the prognosis and outcome in patients with fibromyalgia. Female gender, low socioeconomic status, unemployment, obesity, depression, and history of abuse had negative effects on the outcome ¹⁷.

Overall fibromyalgia prognosis is poor for many patients. Factors associated with poor prognosis include:

• A long duration of disease
• High-stress levels
• Presence of depression or anxiety that has not been adequately treated
• Long-standing avoidance of work
• Alcohol or drug dependence
• Moderate to severe functional impairment

Patients with fibromyalgia are more likely to be hospitalized for any reason compared to the general population.

1. Clauw DJ. Fibromyalgia: A Clinical Review. JAMA. 2014;311(15):1547–1555. doi:10.1001/jama.2014.3266[↩][↩][↩]
2. Wolfe F., Smythe H.A., Yunus M.B., Bennett R.M., Bombardier C., Goldenberg D.L., Tugwell P., Campbell S.M., Abeles M., Clark P., et al. The American College of Rheumatology 1990 Criteria for the classification of fibromyalgia. Arthritis Rheum. 1990;33:160–172. doi: 10.1002/art.1780330203[↩]
3. Wolfe F., Clauw D.J., Fitzcharles M.A., Goldenberg D.L., Katz R.S., Mease P., Russell A.S., Russell I.J., Winfield J.B., Yunus M.B. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62:600–610. doi: 10.1002/acr.20140[↩][↩][↩][↩]
4. Wolfe F, Ross K, Anderson J, et al.. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38(1):1–9. doi: 10.1002/art.1780380104[↩]
5. Choy EH, Mease PJ.. Key symptom domains to be assessed in fibromyalgia (outcome measures in rheumatoid arthritis clinical trials). Rheum Dis Clin North Am. 2009;35(2):329–337. doi: 10.1016/j.rdc.2009.05.002[↩]
6. Gerdle B., Bjork J., Coster L., Henriksson K., Henriksson C., Bengtsson A. Prevalence of widespread pain and associations with work status: A population study. BMC Musculoskelet. Disord. 2008;9:102. doi: 10.1186/1471-2474-9-102[↩]
7. Siracusa R, Paola RD, Cuzzocrea S, Impellizzeri D. Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update. Int J Mol Sci. 2021 Apr 9;22(8):3891. doi: 10.3390/ijms22083891[↩][↩][↩][↩][↩][↩][↩]
8. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007 Mar 9;8:27. doi: 10.1186/1471-2474-8-27[↩]
9. Staud R., Vierck C.J., Cannon R.L., Mauderli A.P., Price D.D. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain. 2001;91:165–175. doi: 10.1016/S0304-3959(00)00432-2[↩][↩]
10. Smythe HA, Moldofsky H. Two contributions to understanding of the “fibrositis” syndrome. Bull Rheum Dis. 1977-1978;28(1):928-31.[↩][↩]
11. Dadabhoy D, Crofford LJ, Spaeth M, Russell IJ, Clauw DJ. Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome. Arthritis Res Ther. 2008;10(4):211. doi: 10.1186/ar2443[↩]
12. Desmeules JA, Cedraschi C, Rapiti E, Baumgartner E, Finckh A, Cohen P, Dayer P, Vischer TL. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum. 2003 May;48(5):1420-9. https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.10893[↩]
13. Gowers WR. A Lecture on Lumbago: Its Lessons and Analogues: Delivered at the National Hospital for the Paralysed and Epileptic. Br Med J. 1904 Jan 16;1(2246):117-21. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2352601/pdf/brmedj08152-0001.pdf[↩]
14. GRAHAM W. The fibrosits syndrome. Bull Rheum Dis. 1953 Apr;3(8):33-4.[↩]
15. Wolfe F. New American College of Rheumatology criteria for fibromyalgia: A twenty-year journey. Arthritis Care Res. 2010;62:583–584. doi: 10.1002/acr.20156[↩][↩]
16. Wolfe F., Clauw D.J., Fitzcharles M.A., Goldenberg D.L., Hauser W., Katz R.L., Mease P.J., Russell A.S., Russell I.J., Walitt B. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin. Arthritis Rheum. 2016;46:319–329. doi: 10.1016/j.semarthrit.2016.08.012[↩]
17. Bhargava J, Hurley JA. Fibromyalgia. [Updated 2023 Jun 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK540974[↩][↩][↩][↩][↩][↩][↩][↩][↩]
18. Brill S, Ablin JN, Goor-Aryeh I, Hyat K, Slefer A, Buskila D; Tel Aviv-Sourasky Medical Center. Prevalence of fibromyalgia syndrome in patients referred to a tertiary pain clinic. J Investig Med. 2012 Apr;60(4):685-8. doi: 10.2310/JIM.0b013e31824963d1[↩]
19. Cabo-Meseguer A., Cerdá-Olmedo G., Trillo-Mata J. Fibromialgia: Prevalencia, perfiles epidemiológicos y costes económicos. Med. Clin. 2017;149:441–448. doi: 10.1016/j.medcli.2017.06.008[↩]
20. Marques A.P., Santo A.d.S.d.E., Berssaneti A.A., Matsutani L.A., Yuan S.L.K. Prevalence of Fibromyalgia: Literature Review Update. Rev. Bras. De Reumatol. Engl. Ed. 2017;57:356–363. doi: 10.1016/j.rbr.2016.10.004[↩]
21. Vincent A, Lahr BD, Wolfe F, Clauw DJ, Whipple MO, Oh TH, Barton DL, St Sauver J. Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken). 2013 May;65(5):786-92. doi: 10.1002/acr.21896[↩][↩]
22. Jones GT, Atzeni F, Beasley M, Flüß E, Sarzi-Puttini P, Macfarlane GJ. The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis Rheumatol. 2015 Feb;67(2):568-75. doi: 10.1002/art.38905[↩]
23. Galvez-Sánchez CM, Reyes Del Paso GA. Diagnostic Criteria for Fibromyalgia: Critical Review and Future Perspectives. J Clin Med. 2020 Apr 23;9(4):1219. doi: 10.3390/jcm9041219[↩][↩][↩]
24. Bellato E., Marini E., Castoldi F., Barbasetti N., Mattei L., Bonasia D.E., Blonna D. Fibromyalgia syndrome: Etiology, pathogenesis, diagnosis, and treatment. Pain Res. Treat. 2012;2012:426130. doi: 10.1155/2012/426130[↩]
25. Fibromyalgia. https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Fibromyalgia[↩]
26. De Sanctis V, Abbasciano V, Soliman AT, et al. The juvenile fibromyalgia syndrome (JFMS): a poorly defined disorder. Acta Biomed. 2019;90(1):134–148. Published 2019 Jan 23. doi:10.23750/abm.v90i1.8141 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6502146[↩][↩][↩]
27. Eraso RM, Bradford NJ, Fontenot CN, Espinoza LR, Gedalia A. Fibromyalgia syndrome in young children: onset at age 10 years and younger. Exp Rheumatol. 2007;25:639–644.[↩]
28. Zernikow B, Gerhold K, Bürk G, Häuser W, Hinze CH, Hospach T, Illhardt A, Mönkemöller K, Richter M, Schnöbel-Müller E, Häfner R. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Definition, diagnosis and therapy of chronic widespread pain and so-called fibromyalgia syndrome in children and adolescents. Systematic literature review and guideline. Schmerz. 2012;26:318–330.[↩]
29. American Pain Society. Glenview: American Pain Society; 2005. Guideline for the management of fibromyalgia syndrome pain in adults and children.[↩]
30. Carville SF, Arendt-Nielsen L, Bliddal H, Blotman F, Branco JC, Buskila D, Da Silva JA, Danneskiold-Samsøe B, Dincer F, Henriksson C, Henriksson KG, Kosek E, Longley K, McCarthy GM, Perrot S, Puszczewicz M, Sarzi-Puttini P, Silman A, Späth M, Choy EH. EULAR. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67:536–541.[↩]
31. Navarro RP. Contemporary management strategies for fibromyalgia. Am J Manag Care. 2009;15(7 suppl):S197–218.[↩]
32. Tran ST, Guite JW, Pantaleao A, Pfeiffer M, Myer GD, Sil S, Thomas SM, Ting TV, Williams SE, Edelheit B, Ounpuu S, Rodriguez-MacClintic J, Zemel L, Zempsky W, Kashikar-Zuck S. Preliminary Outcomes of a Cross-Site Cognitive-Behavioral and Neuromuscular Integrative Training Intervention for Juvenile Fibromyalgia. Arthritis Care Res (Hoboken) 2017;69:413–420.[↩]
33. Eccleston C, Palermo TM, Williams AC, Lewandowski A, Morley S. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD003968. doi: 10.1002/14651858[↩]
34. Yokota S, Kikuchi M, Miyamae T. Juvenile fibromyalgia: Guidance for management. Pediatr Int. 2013;55:403–409.[↩]
35. McLeod JD. Juvenile fibromyalgia syndrome and improved recognition by pediatric primary care providers. J Pediatr Health Care. 2014;28:e9–18.[↩]
36. Mikkelsson M. One year outcome of preadolescents with fibromyalgia. J Rheumatol. 1999;26:674–682.[↩]
37. Kashikar-Zuck S, Parkins IS, Ting TV, Verkamp E, Lynch-Jordan A, Passo M, Graham TB. Controlled follow-up study of physical and psychosocial functioning of adolescents with juvenile primary fibromyalgia syndrome. Rheumatology (Oxford) 2010;49:2204–2209.[↩][↩]
38. Hassett AL, Hilliard PE, Goesling J, Clauw DJ, Harte SE, Brummett CM. Reports of chronic pain in childhood and adolescence among patients at a tertiary care pain clinic. J Pain. 2013;14:1390–7.27.[↩]
39. Gedalia A, García CO, Molina JF, Bradford NJ, Espinoza LR. Fibromyalgia syndrome in pediatric patients. Clin Exp Rheumatol. 2000;18:415–419.[↩]
40. Alfvén G. Recurrent pain, stress, tender points and fibromyalgia in childhood: an exploratory descriptive clinical study. Acta Paediatr. 2012;101:283–291.[↩]
41. Black WR, Kashikar-Zuck S. Exercise interventions for juvenile fibromyalgia: current state and recent advancements. Pain Manag. 2017;7:143–148.[↩]
42. Kashikar-Zuck S, Cunningham N, Sil S, Bromberg MH, Lynch-Jordan AM, Strotman D, Peugh J, Noll J, Ting TV, Powers SW, Lovell DJ, Arnold LM. Long-term outcomes of adolescents with juvenile-onset fibromyalgia in early adulthood. Pediatrics. 2014;133:e592–600.[↩]
43. Staud R. Abnormal pain modulation in patients with spatially distributed chronic pain: fibromyalgia. Rheum Dis Clin North Am. 2009 May;35(2):263-74. doi: 10.1016/j.rdc.2009.05.006[↩][↩][↩]
44. Bohn D., Bernardy K., Wolfe F., Häuser W. The association among childhood maltreatment, somatic symptom intensity, depression, and somatoform dissociative symptoms in patients with fibromyalgia syndrome: A single-center cohort study. J. Trauma Dissociation. 2013;14:342–358. doi: 10.1080/15299732.2012.736930[↩]
45. Häuser W., Kosseva M., Üceyler N., Klose P., Sommer C. Emotional, physical, and sexual abuse in fibromyalgia syndrome: A systematic review with meta-analysis. Arthritis Care Res. 2011;63:808–820. doi: 10.1002/acr.20328[↩]
46. Sarzi-Puttini P, Atzeni F, Mease PJ. Chronic widespread pain: from peripheral to central evolution. Best Pract Res Clin Rheumatol. 2011 Apr;25(2):133-9. doi: 10.1016/j.berh.2011.04.001[↩]
47. Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology to therapy. Nat Rev Rheumatol. 2011 Jul 19;7(9):518-27. doi: 10.1038/nrrheum.2011.98[↩]
48. Buskila D, Sarzi-Puttini P. Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome. Arthritis Res Ther. 2006;8(5):218. doi: 10.1186/ar2005[↩]
49. Oertel B., Lotsch J. Genetic mutations that prevent pain: Implications for future pain medication. Pharmacogenomics. 2008;9:179–194. doi: 10.2217/14622416.9.2.179[↩][↩]
50. Meyer H.P. Myofascial pain syndrome and its suggested role in the pathogenesis and treatment of fibromyalgia syndrome. Curr. Pain Headache Rep. 2002;6:274–283. doi: 10.1007/s11916-002-0048-z[↩]
51. Clauw D.J. Fibromyalgia and related conditions. Mayo Clin. Proc. 2015;90:680–692. doi: 10.1016/j.mayocp.2015.03.014[↩]
52. Malatji B.G., Mason S., Mienie L.J., Wevers R.A., Meyer H., van Reenen M., Reinecke C.J. The GC-MS metabolomics signature in patients with fibromyalgia syndrome directs to dysbiosis as an aspect contributing factor of FMS pathophysiology. Metabolomics. 2019;15:54. doi: 10.1007/s11306-019-1513-6[↩]
53. Bradley L.A. Pathophysiology of fibromyalgia. Am. J. Med. 2009;122(Suppl. S12):S22–S30. doi: 10.1016/j.amjmed.2009.09.008[↩]
54. Yunus M.B., Khan M.A., Rawlings K.K., Green J.R., Olson J.M., Shah S. Genetic linkage analysis of multicase families with fibromyalgia syndrome. J. Rheumatol. 1999;26:408–412.[↩]
55. Muir W.W., 3rd, Woolf C.J. Mechanisms of pain and their therapeutic implications. J. Am. Vet. Med. Assoc. 2001;219:1346–1356. doi: 10.2460/javma.2001.219.1346[↩]
56. Vierck C.J., Jr. Mechanisms underlying development of spatially distributed chronic pain (fibromyalgia) Pain. 2006;124:242–263. doi: 10.1016/j.pain.2006.06.001[↩][↩]
57. Staud R., Nagel S., Robinson M.E., Price D.D. Enhanced central pain processing of fibromyalgia patients is maintained by muscle afferent input: A randomized, double-blind, placebo-controlled study. Pain. 2009;145:96–104. doi: 10.1016/j.pain.2009.05.020[↩]
58. Brosschot J.F. Cognitive-emotional sensitization and somatic health complaints. Scand. J. Psychol. 2002;43:113–121. doi: 10.1111/1467-9450.00276[↩]
59. Jackson P.L., Meltzoff A.N., Decety J. How do we perceive the pain of others? A window into the neural processes involved in empathy. Neuroimage. 2005;24:771–779. doi: 10.1016/j.neuroimage.2004.09.006[↩]
60. Collado A., Gomez E., Coscolla R., Sunyol R., Sole E., Rivera J., Altarriba E., Carbonell J., Castells X. Work, family and social environment in patients with Fibromyalgia in Spain: An epidemiological study: EPIFFAC study. BMC Health Serv. Res. 2014;14:513. doi: 10.1186/s12913-014-0513-5[↩]
61. O’Brien A.T., Deitos A., Trinanes Pego Y., Fregni F., Carrillo-de-la-Pena M.T. Defective Endogenous Pain Modulation in Fibromyalgia: A Meta-Analysis of Temporal Summation and Conditioned Pain Modulation Paradigms. J. Pain. 2018;19:819–836. doi: 10.1016/j.jpain.2018.01.010[↩]
62. Harris R.E., Clauw D.J. Imaging central neurochemical alterations in chronic pain with proton magnetic resonance spectroscopy. Neurosci. Lett. 2012;520:192–196. doi: 10.1016/j.neulet.2012.03.042[↩]
63. Sluka K.A., O’Donnell J.M., Danielson J., Rasmussen L.A. Regular physical activity prevents development of chronic pain and activation of central neurons. J. Appl. Physiol. 2013;114:725–733. doi: 10.1152/japplphysiol.01317.2012[↩]
64. Bobinski F., Ferreira T.A.A., Cordova M.M., Dombrowski P.A., da Cunha C., Santo C., Poli A., Pires R.G.W., Martins-Silva C., Sluka K.A., et al. Role of brainstem serotonin in analgesia produced by low-intensity exercise on neuropathic pain after sciatic nerve injury in mice. Pain. 2015;156:2595–2606. doi: 10.1097/j.pain.0000000000000372[↩]
65. Nugraha B., Karst M., Engeli S., Gutenbrunner C. Brain-derived neurotrophic factor and exercise in fibromyalgia syndrome patients: A mini review. Rheumatol. Int. 2012;32:2593–2599. doi: 10.1007/s00296-011-2348-2[↩]
66. Giovengo SL, Russell IJ, Larson AA. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol. 1999 Jul;26(7):1564-9.[↩]
67. Baumeister D., Eich W., Saft S., Geisel O., Hellweg R., Finn A., Svensson C.I., Tesarz J. No evidence for altered plasma NGF and BDNF levels in fibromyalgia patients. Sci. Rep. 2019;9:13667. doi: 10.1038/s41598-019-49403-7[↩]
68. Slade G.D., Conrad M.S., Diatchenko L., Rashid N.U., Zhong S., Smith S., Rhodes J., Medvedev A., Makarov S., Maixner W., et al. Cytokine biomarkers and chronic pain: Association of genes, transcription, and circulating proteins with temporomandibular disorders and widespread palpation tenderness. Pain. 2011;152:2802–2812. doi: 10.1016/j.pain.2011.09.005[↩]
69. Sturgill J., McGee E., Menzies V. Unique cytokine signature in the plasma of patients with fibromyalgia. J. Immunol. Res. 2014;2014:938576. doi: 10.1155/2014/938576[↩]
70. Mendieta D., De la Cruz-Aguilera D.L., Barrera-Villalpando M.I., Becerril-Villanueva E., Arreola R., Hernandez-Ferreira E., Perez-Tapia S.M., Perez-Sanchez G., Garces-Alvarez M.E., Aguirre-Cruz L., et al. IL-8 and IL-6 primarily mediate the inflammatory response in fibromyalgia patients. J. Neuroimmunol. 2016;290:22–25. doi: 10.1016/j.jneuroim.2015.11.011[↩][↩][↩]
71. Littlejohn G., Guymer E. Neurogenic inflammation in fibromyalgia. Semin. Immunopathol. 2018;40:291–300. doi: 10.1007/s00281-018-0672-2[↩]
72. Bote M.E., Garcia J.J., Hinchado M.D., Ortega E. An exploratory study of the effect of regular aquatic exercise on the function of neutrophils from women with fibromyalgia: Role of IL-8 and noradrenaline. Brain Behav. Immunol. 2014;39:107–112. doi: 10.1016/j.bbi.2013.11.009[↩]
73. Kadetoff D., Lampa J., Westman M., Andersson M., Kosek E. Evidence of central inflammation in fibromyalgia-increased cerebrospinal fluid interleukin-8 levels. J. Neuroimmunol. 2012;242:33–38. doi: 10.1016/j.jneuroim.2011.10.013[↩]
74. Coskun Benlidayi I. Role of inflammation in the pathogenesis and treatment of fibromyalgia. Rheumatol. Int. 2019;39:781–791. doi: 10.1007/s00296-019-04251-6[↩]
75. Kosek E., Altawil R., Kadetoff D., Finn A., Westman M., Le Maitre E., Andersson M., Jensen-Urstad M., Lampa J. Evidence of different mediators of central inflammation in dysfunctional and inflammatory pain–interleukin-8 in fibromyalgia and interleukin-1 beta in rheumatoid arthritis. J. Neuroimmunol. 2015;280:49–55. doi: 10.1016/j.jneuroim.2015.02.002[↩]
76. Bote M.E., Garcia J.J., Hinchado M.D., Ortega E. Inflammatory/stress feedback dysregulation in women with fibromyalgia. Neuroimmunomodulation. 2012;19:343–351. doi: 10.1159/000341664[↩]
77. Ranzolin A., Duarte A.L., Bredemeier M., da Costa Neto C.A., Ascoli B.M., Wollenhaupt-Aguiar B., Kapczinski F., Xavier R.M. Evaluation of cytokines, oxidative stress markers and brain-derived neurotrophic factor in patients with fibromyalgia–A controlled cross-sectional study. Cytokine. 2016;84:25–28. doi: 10.1016/j.cyto.2016.05.011[↩]
78. Imamura M, Targino RA, Hsing WT, Imamura S, Azevedo RS, Boas LS, Tozetto-Mendoza TR, Alfieri FM, Filippo TR, Battistella LR. Concentration of cytokines in patients with osteoarthritis of the knee and fibromyalgia. Clin Interv Aging. 2014 Jun 12;9:939-44. doi: 10.2147/CIA.S60330[↩]
79. Mastrangelo F., Frydas I., Ronconi G., Kritas S.K., Tettamanti L., Caraffa A.C., DOvidio C., Younes A., Gallenga C.E., Conti P. Low-grade chronic inflammation mediated by mast cells in fibromyalgia: Role of IL-37. J. Biol. Regul. Homeost. Agents. 2018;32:195–198.[↩]
80. Gregory N.S., Brito R.G., Fusaro M., Sluka K.A. ASIC3 Is Required for Development of Fatigue-Induced Hyperalgesia. Mol. Neurobiol. 2016;53:1020–1030. doi: 10.1007/s12035-014-9055-4[↩]
81. Cicuttini F.M., Wluka A.E. Not just loading and age: The dynamics of osteoarthritis, obesity and inflammation. Med. J. Aust. 2016;204:47. doi: 10.5694/mja15.01069[↩]
82. Rossi H.L., Luu A.K., DeVilbiss J.L., Recober A. Obesity increases nociceptive activation of the trigeminal system. Eur. J. Pain. 2013;17:649–653. doi: 10.1002/j.1532-2149.2012.00230.x[↩]
83. Rossi H.L., Luu A.K., Kothari S.D., Kuburas A., Neubert J.K., Caudle R.M., Recober A. Effects of diet-induced obesity on motivation and pain behavior in an operant assay. Neuroscience. 2013;235:87–95. doi: 10.1016/j.neuroscience.2013.01.019[↩]
84. Smart P.A., Waylonis G.W., Hackshaw K.V. Immunologic profile of patients with fibromyalgia. Am. J. Phys. Med. Rehabil. 1997;76:231–234. doi: 10.1097/00002060-199705000-00014[↩][↩]
85. Batista E.D., Andretta A., de Miranda R.C., Nehring J., Dos Santos Paiva E., Schieferdecker M.E. Food intake assessment and quality of life in women with fibromyalgia. Rev. Bras. Reumatol. Engl. Ed. 2016;56:105–110. doi: 10.1016/j.rbr.2015.03.012[↩][↩]
86. Rokyta R., Holecek V., Pekarkova I., Krejcova J., Racek J., Trefil L., Yamamotova A. Free radicals after painful stimulation are influenced by antioxidants and analgesics. Neuro Endocrinol. Lett. 2003;24:304–309.[↩]
87. Mogil J.S. Pain genetics: Past, present and future. Trends Genet. 2012;28:258–266. doi: 10.1016/j.tig.2012.02.004[↩]
88. Arnold L.M., Fan J., Russell I.J., Yunus M.B., Khan M.A., Kushner I., Olson J.M., Iyengar S.K. The fibromyalgia family study: A genome-wide linkage scan study. Arthritis Rheum. 2013;65:1122–1128. doi: 10.1002/art.37842[↩]
89. Mergener M., Becker R.M., dos Santos A.F., dos Santos G.A., de Andrade F.M. Influence of the interaction between environmental quality and T102C SNP in the HTR2A gene on fibromyalgia susceptibility. Rev. Bras. Reum. 2011;51:594–602.[↩]
90. Mickle AD, Shepherd AJ, Mohapatra DP. Sensory TRP channels: the key transducers of nociception and pain. Prog Mol Biol Transl Sci. 2015;131:73-118. doi: 10.1016/bs.pmbts.2015.01.002[↩]
91. Lee Y.H., Choi S.J., Ji J.D., Song G.G. Candidate gene studies of fibromyalgia: A systematic review and meta-analysis. Rheumatol. Int. 2012;32:417–426. doi: 10.1007/s00296-010-1678-9[↩]
92. Docampo E., Escaramis G., Gratacos M., Villatoro S., Puig A., Kogevinas M., Collado A., Carbonell J., Rivera J., Vidal J., et al. Genome-wide analysis of single nucleotide polymorphisms and copy number variants in fibromyalgia suggest a role for the central nervous system. Pain. 2014;155:1102–1109. doi: 10.1016/j.pain.2014.02.016[↩]
93. Wood P.B., Schweinhardt P., Jaeger E., Dagher A., Hakyemez H., Rabiner E.A., Bushnell M.C., Chizh B.A. Fibromyalgia patients show an abnormal dopamine response to pain. Eur. J. Neurosci. 2007;25:3576–3582. doi: 10.1111/j.1460-9568.2007.05623.x[↩]
94. Gold S.J., Ni Y.G., Dohlman H.G., Nestler E.J. Regulators of G-protein signaling (RGS) proteins: Region-specific expression of nine subtypes in rat brain. J. Neurosci. 1997;17:8024–8037. doi: 10.1523/JNEUROSCI.17-20-08024.1997[↩]
95. Lu A.T., Ogdie M.N., Jarvelin M.R., Moilanen I.K., Loo S.K., McCracken J.T., McGough J.J., Yang M.H., Peltonen L., Nelson S.F., et al. Association of the cannabinoid receptor gene (CNR1) with ADHD and post-traumatic stress disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008;147B:1488–1494. doi: 10.1002/ajmg.b.30693[↩]
96. Park J.M., Choi M.G., Cho Y.K., Lee I.S., Kim S.W., Choi K.Y., Chung I.S. Cannabinoid receptor 1 gene polymorphism and irritable bowel syndrome in the Korean population: A hypothesis-generating study. J. Clin. Gastroenterol. 2011;45:45–49. doi: 10.1097/MCG.0b013e3181dd1573[↩]
97. Bleakman D., Alt A., Nisenbaum E.S. Glutamate receptors and pain. Semin. Cell Dev. Biol. 2006;17:592–604. doi: 10.1016/j.semcdb.2006.10.008[↩]
98. Crofford L.J., Pillemer S.R., Kalogeras K.T., Cash J.M., Michelson D., Kling M.A., Sternberg E.M., Gold P.W., Chrousos G.P., Wilder R.L. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum. 1994;37:1583–1592. doi: 10.1002/art.1780371105[↩]
99. McCain G.A., Tilbe K.S. Diurnal hormone variation in fibromyalgia syndrome: A comparison with rheumatoid arthritis. J. Rheumatol. Suppl. 1989;19:154–157.[↩]
100. McLean S.A., Williams D.A., Harris R.E., Kop W.J., Groner K.H., Ambrose K., Lyden A.K., Gracely R.H., Crofford L.J., Geisser M.E., et al. Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgia. Arthritis Rheum. 2005;52:3660–3669. doi: 10.1002/art.21372[↩][↩]
101. Weissbecker I., Floyd A., Dedert E., Salmon P., Sephton S. Childhood trauma and diurnal cortisol disruption in fibromyalgia syndrome. Psychoneuroendocrinology. 2006;31:312–324. doi: 10.1016/j.psyneuen.2005.08.009[↩]
102. Crofford L.J., Young E.A., Engleberg N.C., Korszun A., Brucksch C.B., McClure L.A., Brown M.B., Demitrack M.A. Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain Behav. Immun. 2004;18:314–325. doi: 10.1016/j.bbi.2003.12.011[↩]
103. Abeles A.M., Pillinger M.H., Solitar B.M., Abeles M. Narrative review: The pathophysiology of fibromyalgia. Ann. Intern. Med. 2007;146:726–734. doi: 10.7326/0003-4819-146-10-200705150-00006[↩]
104. Rea K., Dinan T.G., Cryan J.F. The microbiome: A key regulator of stress and neuroinflammation. Neurobiol. Stress. 2016;4:23–33. doi: 10.1016/j.ynstr.2016.03.001[↩]
105. McLean S.A., Williams D.A., Stein P.K., Harris R.E., Lyden A.K., Whalen G., Park K.M., Liberzon I., Sen A., Gracely R.H., et al. Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. Neuropsychopharmacology. 2006;31:2776–2782. doi: 10.1038/sj.npp.1301200[↩]
106. Wingenfeld K., Heim C., Schmidt I., Wagner D., Meinlschmidt G., Hellhammer D.H. HPA axis reactivity and lymphocyte glucocorticoid sensitivity in fibromyalgia syndrome and chronic pelvic pain. Psychosom. Med. 2008;70:65–72. doi: 10.1097/PSY.0b013e31815ff3ce[↩]
107. Bennett R.M., Cook D.M., Clark S.R., Burckhardt C.S., Campbell S.M. Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. J. Rheumatol. 1997;24:1384–1389.[↩]
108. Paul-Savoie E., Marchand S., Morin M., Bourgault P., Brissette N., Rattanavong V., Cloutier C., Bissonnette A., Potvin S. Is the deficit in pain inhibition in fibromyalgia influenced by sleep impairments? Open Rheumatol. J. 2012;6:296–302. doi: 10.2174/1874312901206010296[↩]
109. Okifuji A., Turk D.C. Sex hormones and pain in regularly menstruating women with fibromyalgia syndrome. J. Pain. 2006;7:851–859. doi: 10.1016/j.jpain.2006.04.005[↩]
110. Koca T., Kocyigit B., Seyithanoglu M., Berk E. The Importance of G-protein Coupled Estrogen Receptor in Patients with Fibromyalgia. Arch. Rheumatol. 2019;34:419–425. doi: 10.5606/ArchRheumatol.2019.7236[↩]
111. Epstein S.A., Kay G., Clauw D., Heaton R., Klein D., Krupp L., Kuck J., Leslie V., Masur D., Wagner M., et al. Psychiatric disorders in patients with fibromyalgia. A multicenter investigation. Psychosomatics. 1999;40:57–63. doi: 10.1016/S0033-3182(99)71272-7[↩]
112. Leino P., Magni G. Depressive and distress symptoms as predictors of low back pain, neck-shoulder pain, and other musculoskeletal morbidity: A 10-year follow-up of metal industry employees. Pain. 1993;53:89–94. doi: 10.1016/0304-3959(93)90060-3[↩]
113. Giesecke T., Gracely R.H., Williams D.A., Geisser M.E., Petzke F.W., Clauw D.J. The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum. 2005;52:1577–1584. doi: 10.1002/art.21008[↩]
114. O’Malley P.G., Balden E., Tomkins G., Santoro J., Kroenke K., Jackson J.L. Treatment of fibromyalgia with antidepressants: A meta-analysis. J. Gen. Intern. Med. 2000;15:659–666. doi: 10.1046/j.1525-1497.2000.06279.x[↩]
115. Jackson J.L., O’Malley P.G., Tomkins G., Balden E., Santoro J., Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: A meta-analysis. Am. J. Med. 2000;108:65–72. doi: 10.1016/S0002-9343(99)00299-5[↩]
116. Tomkins G.E., Jackson J.L., O’Malley P.G., Balden E., Santoro J.E. Treatment of chronic headache with antidepressants: A meta-analysis. Am. J. Med. 2001;111:54–63. doi: 10.1016/S0002-9343(01)00762-8[↩]
117. Moret C., Briley M. Antidepressants in the treatment of fibromyalgia. Neuropsychiatr. Dis. Treat. 2006;2:537–548. doi: 10.2147/nedt.2006.2.4.537[↩]
118. Jennings E.M., Okine B.N., Roche M., Finn D.P. Stress-induced hyperalgesia. Prog. Neurobiol. 2014;121:1–18. doi: 10.1016/j.pneurobio.2014.06.003[↩]
119. Michaux G.P.N., Magerl W., Anton F., Treede R.D. Experimental characterization of the effects of acute stresslike doses of hydrocortisone in human neurogenic hyperalgesia models. Pain. 2012;153:420–428. doi: 10.1016/j.pain.2011.10.043[↩]
120. Kuehl L.K., Michaux G.P., Richter S., Schachinger H., Anton F. Increased basal mechanical pain sensitivity but decreased perceptual wind-up in a human model of relative hypocortisolism. Pain. 2010;149:539–546. doi: 10.1016/j.pain.2010.03.026[↩]
121. Suarez-Roca H., Silva J.A., Arcaya J.L., Quintero L., Maixner W., Pinerua-Shuhaibar L. Role of mu-opioid and NMDA receptors in the development and maintenance of repeated swim stress-induced thermal hyperalgesia. Behav. Brain Res. 2006;167:205–211. doi: 10.1016/j.bbr.2005.09.006[↩]
122. Nasu T., Taguchi T., Mizumura K. Persistent deep mechanical hyperalgesia induced by repeated cold stress in rats. Eur. J. Pain. 2010;14:236–244. doi: 10.1016/j.ejpain.2009.05.009[↩]
123. Nishiyori M., Uchida H., Nagai J., Araki K., Mukae T., Kishioka S., Ueda H. Permanent relief from intermittent cold stress-induced fibromyalgia-like abnormal pain by repeated intrathecal administration of antidepressants. Mol. Pain. 2011;7:69. doi: 10.1186/1744-8069-7-69[↩]
124. Gregory N.S., Gibson-Corley K., Frey-Law L., Sluka K.A. Fatigue-enhanced hyperalgesia in response to muscle insult: Induction and development occur in a sex-dependent manner. Pain. 2013;154:2668–2676. doi: 10.1016/j.pain.2013.07.047[↩]
125. Khasar S.G., Dina O.A., Green P.G., Levine J.D. Sound stress-induced long-term enhancement of mechanical hyperalgesia in rats is maintained by sympathoadrenal catecholamines. J. Pain. 2009;10:1073–1077. doi: 10.1016/j.jpain.2009.04.005[↩]
126. Sluka K.A., Danielson J., Rasmussen L., DaSilva L.F. Exercise-induced pain requires NMDA receptor activation in the medullary raphe nuclei. Med. Sci. Sports Exerc. 2012;44:420–427. doi: 10.1249/MSS.0b013e31822f490e[↩][↩]
127. Quintero J.E., Dooley D.J., Pomerleau F., Huettl P., Gerhardt G.A. Amperometric measurement of glutamate release modulation by gabapentin and pregabalin in rat neocortical slices: Role of voltage-sensitive Ca2+ alpha2delta-1 subunit. J. Pharm. Exp. 2011;338:240–245. doi: 10.1124/jpet.110.178384[↩]
128. Suarez-Roca H., Leal L., Silva J.A., Pinerua-Shuhaibar L., Quintero L. Reduced GABA neurotransmission underlies hyperalgesia induced by repeated forced swimming stress. Behav. Brain Res. 2008;189:159–169. doi: 10.1016/j.bbr.2007.12.022[↩]
129. Hata T., Itoh E., Kawabata A. Changes in CNS levels of serotonin and its metabolite in SART-stressed (repeatedly cold-stressed) rats. Jpn. J. Pharm. 1991;56:101–104. doi: 10.1016/S0021-5198(19)39903-2[↩]
130. Finan P.H., Goodin B.R., Smith M.T. The association of sleep and pain: An update and a path forward. J. Pain. 2013;14:1539–1552. doi: 10.1016/j.jpain.2013.08.007[↩]
131. Mundal I., Grawe R.W., Bjorngaard J.H., Linaker O.M., Fors E.A. Prevalence and long-term predictors of persistent chronic widespread pain in the general population in an 11-year prospective study: The HUNT study. BMC Musculoskelet. Disord. 2014;15:213. doi: 10.1186/1471-2474-15-213[↩]
132. Haack M., Sanchez E., Mullington J.M. Elevated inflammatory markers in response to prolonged sleep restriction are associated with increased pain experience in healthy volunteers. Sleep. 2007;30:1145–1152. doi: 10.1093/sleep/30.9.1145[↩][↩]
133. Irwin M.R., Olmstead R., Carrillo C., Sadeghi N., Fitzgerald J.D., Ranganath V.K., Nicassio P.M. Sleep loss exacerbates fatigue, depression, and pain in rheumatoid arthritis. Sleep. 2012;35:537–543. doi: 10.5665/sleep.1742[↩]
134. Smith M.T., Edwards R.R., McCann U.D., Haythornthwaite J.A. The effects of sleep deprivation on pain inhibition and spontaneous pain in women. Sleep. 2007;30:494–505. doi: 10.1093/sleep/30.4.494[↩]
135. Parrino L., Grassi A., Milioli G. Cyclic alternating pattern in polysomnography: What is it and what does it mean? Curr. Opin. Pulm. Med. 2014;20:533–541. doi: 10.1097/MCP.0000000000000100[↩]
136. Rizzi M., Sarzi-Puttini P., Atzeni F., Capsoni F., Andreoli A., Pecis M., Colombo S., Carrabba M., Sergi M. Cyclic alternating pattern: A new marker of sleep alteration in patients with fibromyalgia? J. Rheumatol. 2004;31:1193–1199.[↩]
137. Tiede W., Magerl W., Baumgartner U., Durrer B., Ehlert U., Treede R.D. Sleep restriction attenuates amplitudes and attentional modulation of pain-related evoked potentials, but augments pain ratings in healthy volunteers. Pain. 2010;148:36–42. doi: 10.1016/j.pain.2009.08.029[↩]
138. Moldofsky H., Scarisbrick P., England R., Smythe H. Musculosketal symptoms and non-REM sleep disturbance in patients with “fibrositis syndrome” and healthy subjects. Psychosom. Med. 1975;37:341–351. doi: 10.1097/00006842-197507000-00008[↩][↩]
139. Gottshall J.L., Adams Z.M., Forgacs P.B., Schiff N.D. Daytime Central Thalamic Deep Brain Stimulation Modulates Sleep Dynamics in the Severely Injured Brain: Mechanistic Insights and a Novel Framework for Alpha-Delta Sleep Generation. Front. Neurol. 2019;10:20. doi: 10.3389/fneur.2019.00020[↩]
140. Vijayan S., Klerman E.B., Adler G.K., Kopell N.J. Thalamic mechanisms underlying alpha-delta sleep with implications for fibromyalgia. J. Neurophysiol. 2015;114:1923–1930. doi: 10.1152/jn.00280.2015[↩]
141. Roizenblatt S., Moldofsky H., Benedito-Silva A.A., Tufik S. Alpha sleep characteristics in fibromyalgia. Arthritis Rheum. 2001;44:222–230. doi: 10.1002/1529-0131(200101)44:1<222::AID-ANR29>3.0.CO;2-K[↩]
142. Steriade M. Corticothalamic resonance, states of vigilance and mentation. Neuroscience. 2000;101:243–276. doi: 10.1016/S0306-4522(00)00353-5[↩]
143. Steriade M., Deschenes M. The thalamus as a neuronal oscillator. Brain Res. 1984;320:1–63. doi: 10.1016/0165-0173(84)90017-1[↩]
144. Steriade M., McCormick D.A., Sejnowski T.J. Thalamocortical oscillations in the sleeping and aroused brain. Science. 1993;262:679–685. doi: 10.1126/science.8235588[↩]
145. Steriade M., Amzica F. Coalescence of sleep rhythms and their chronology in corticothalamic networks. Sleep Res. Online. 1998;1:1–10.[↩]
146. Principe J.C., Smith J.R. Sleep spindle characteristics as a function of age. Sleep. 1982;5:73–84.[↩]
147. Landis C.A., Lentz M.J., Rothermel J., Buchwald D., Shaver J.L. Decreased sleep spindles and spindle activity in midlife women with fibromyalgia and pain. Sleep. 2004;27:741–750. doi: 10.1093/sleep/27.4.741[↩]
148. Kulkarni P.M., Xiao Z., Robinson E.J., Jami A.S., Zhang J., Zhou H., Henin S.E., Liu A.A., Osorio R.S., Wang J., et al. A deep learning approach for real-time detection of sleep spindles. J. Neural Eng. 2019;16:036004. doi: 10.1088/1741-2552/ab0933[↩]
149. Caravan B., Hu L., Veyg D., Kulkarni P., Zhang Q., Chen Z.S., Wang J. Sleep spindles as a diagnostic and therapeutic target for chronic pain. Mol. Pain. 2020;16:1744806920902350. doi: 10.1177/1744806920902350[↩]
150. Wolfe F., Clauw D.J., Fitzcharles M.-A., Goldenberg D.L., Häuser W., Katz R.L., Mease P.J., Russell A.S., Russell I.J., Walitt B. 2016 Revisions to the 2010/2011 Fibromyalgia Diagnostic Criteria. Semin. Arthritis Rheum. 2016;46:319–329. doi: 10.1016/j.semarthrit.2016.08.012[↩]
151. Wolfe F., Clauw D.J., Fitzcharles M.-A., Goldenberg D.L., Häuser W., Katz R.L., Mease P.J., Russell A.S., Russell I.J., Walitt B. 2016 Revisions to the 2010/2011 Fibromyalgia Diagnostic Criteria. Semin. Arthritis Rheum. 2016;46:319–329. https://doi.org/10.1016/j.semarthrit.2016.08.012[↩][↩][↩][↩][↩][↩][↩][↩]
152. Wang S.-M., Han C., Lee S.-J., Patkar A.A., Masand P.S., Pae C.-U. Fibromyalgia Diagnosis: A Review of the Past, Present and Future. Expert Rev. Neurother. 2015;15:667–679. doi: 10.1586/14737175.2015.1046841[↩]
153. Egloff N, von Känel R, Müller V, et al. Implications of proposed fibromyalgia criteria across other functional pain syndromes. Scand J Rheumatol. 2015;44(5):416–424.[↩]
154. Wolfe F, Egloff N, Häuser W. Widespread Pain and Low Widespread Pain Index Scores among Fibromyalgia-positive Cases Assessed with the 2010/2011 Fibromyalgia Criteria. J Rheumatol. 2016;43(9):1743–1748.[↩]
155. Wolfe F, Clauw DJ, Fitzcharles M-A, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319–329.[↩]
156. Arnold LM, Bennett RM, Crofford LJ, et al. AAPT Diagnostic Criteria for Fibromyalgia. J Pain. 2019;20(6):611–628[↩]
157. Wolfe F. Letter to the editor, “Fibromyalgia Criteria. J Pain. 2019;20(6):739–740.[↩]
158. Arnold LM, Bennett RM, Crofford LJ, Dean LE, Clauw DJ, Goldenberg DL, Fitzcharles MA, Paiva ES, Staud R, Sarzi-Puttini P, Buskila D, Macfarlane GJ. AAPT Diagnostic Criteria for Fibromyalgia. J Pain. 2019 Jun;20(6):611-628. doi: 10.1016/j.jpain.2018.10.008[↩]
159. Bernardy K, Klose P, Busch AJ, Choy EHS, Häuser W. Cognitive behavioural therapies for fibromyalgia. Cochrane Database Syst Rev. 2013;(9):CD009796[↩]
160. Lazaridou A, Kim J, Cahalan CM, et al. Effects of Cognitive-Behavioral Therapy (CBT) on Brain Connectivity Supporting Catastrophizing in Fibromyalgia. Clin J Pain. 2017;33(3):215–221.[↩]
161. Living with Fibromyalgia, Drugs Approved to Manage Pain. https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm107802.htm[↩][↩]
162. Bagis S., Tamer L., Sahin G., Bilgin R., Guler H., Ercan B., Erdogan C. Free radicals and antioxidants in primary fibromyalgia: An oxidative stress disorder? Rheumatol. Int. 2005;25:188–190. doi: 10.1007/s00296-003-0427-8[↩]
163. Miranda-Díaz A.G., Rodríguez-Lara S.Q. The Role of Oxidants/Antioxidants, Mitochondrial. Dysfunction, and Autophagy in Fibromyalgia. In: Wilke W.S., editor. Discussions of Unusual Topics in Fibromyalgia. Inthech; London, UK: 2018.[↩]
164. Quintans-Junior L.J., Brito R.G., Quintans J.S.S., Santos P.L., Camargo Z.T., Barreto P.A., Arrigoni-Blank M.F., Lucca-Junior W., Scotti L., Scotti M.T., et al. Nanoemulsion Thermoreversible Pluronic F127-Based Hydrogel Containing Hyptis pectinata (Lamiaceae) Leaf Essential Oil Produced a Lasting Anti-hyperalgesic Effect in Chronic Noninflammatory Widespread Pain in Mice. Mol. Neurobiol. 2018;55:1665–1675. doi: 10.1007/s12035-017-0438-1[↩]
165. Lister R.E. An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome. J. Int. Med. Res. 2002;30:195–199. doi: 10.1177/147323000203000213[↩]
166. Oliveira M.G., Brito R.G., Santos P.L., Araujo-Filho H.G., Quintans J.S., Menezes P.P., Serafini M.R., Carvalho Y.M., Silva J.C., Almeida J.R., et al. Alpha-Terpineol, a monoterpene alcohol, complexed with beta-cyclodextrin exerts antihyperalgesic effect in animal model for fibromyalgia aided with docking study. Chem. Biol. Interact. 2016;254:54–62. doi: 10.1016/j.cbi.2016.05.029[↩]
167. Quintans-Junior L.J., Araujo A.A., Brito R.G., Santos P.L., Quintans J.S., Menezes P.P., Serafini M.R., Silva G.F., Carvalho F.M., Brogden N.K., et al. Beta-caryophyllene, a dietary cannabinoid, complexed with beta-cyclodextrin produced anti-hyperalgesic effect involving the inhibition of Fos expression in superficial dorsal horn. Life Sci. 2016;149:34–41. doi: 10.1016/j.lfs.2016.02.049[↩]
168. Casanueva B., Rodero B., Quintial C., Llorca J., Gonzalez-Gay M.A. Short-term efficacy of topical capsaicin therapy in severely affected fibromyalgia patients. Rheumatol. Int. 2013;33:2665–2670. doi: 10.1007/s00296-012-2490-5[↩]
169. Fusco R., Siracusa R., D’Amico R., Peritore A.F., Cordaro M., Gugliandolo E., Crupi R., Impellizzeri D., Cuzzocrea S., Di Paola R. Melatonin Plus Folic Acid Treatment Ameliorates Reserpine-Induced Fibromyalgia: An Evaluation of Pain, Oxidative Stress, and Inflammation. Antioxidants. 2019;8:628. doi: 10.3390/antiox8120628[↩]
170. de Zanette S.A., Vercelino R., Laste G., Rozisky J.R., Schwertner A., Machado C.B., Xavier F., de Souza I.C., Deitos A., Torres I.L., et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: A phase II, randomized, double-dummy, controlled trial. BMC Pharm. Toxicol. 2014;15:40. doi: 10.1186/2050-6511-15-40[↩]
171. Hussain S.A., Al K., II, Jasim N.A., Gorial F.I. Adjuvant use of melatonin for treatment of fibromyalgia. J. Pineal Res. 2011;50:267–271. doi: 10.1111/j.1600-079X.2010.00836.x[↩]
172. Cordero M.D., Cotan D., del-Pozo-Martin Y., Carrion A.M., de Miguel M., Bullon P., Sanchez-Alcazar J.A. Oral coenzyme Q10 supplementation improves clinical symptoms and recovers pathologic alterations in blood mononuclear cells in a fibromyalgia patient. Nutrition. 2012;28:1200–1203. doi: 10.1016/j.nut.2012.03.018[↩]
173. Cordero M.D., Cano-Garcia F.J., Alcocer-Gomez E., De Miguel M., Sanchez-Alcazar J.A. Oxidative stress correlates with headache symptoms in fibromyalgia: Coenzyme Q(1)(0) effect on clinical improvement. PLoS ONE. 2012;7:e35677. doi: 10.1371/journal.pone.0035677[↩]
174. Sawaddiruk P., Apaijai N., Paiboonworachat S., Kaewchur T., Kasitanon N., Jaiwongkam T., Kerdphoo S., Chattipakorn N., Chattipakorn S.C. Coenzyme Q10 supplementation alleviates pain in pregabalin-treated fibromyalgia patients via reducing brain activity and mitochondrial dysfunction. Free Radic. Res. 2019;53:901–909. doi: 10.1080/10715762.2019.1645955[↩]
175. Joustra M.L., Minovic I., Janssens K.A.M., Bakker S.J.L., Rosmalen J.G.M. Vitamin and mineral status in chronic fatigue syndrome and fibromyalgia syndrome: A systematic review and meta-analysis. PLoS ONE. 2017;12:e0176631. doi: 10.1371/journal.pone.017663[↩]
176. Ellis S.D., Kelly S.T., Shurlock J.H., Hepburn A.L.N. The role of vitamin D testing and replacement in fibromyalgia: A systematic literature review. BMC Rheumatol. 2018;2:28. doi: 10.1186/s41927-018-0035-6[↩]
177. Gugliandolo E., Peritore A.F., Piras C., Cuzzocrea S., Crupi R. Palmitoylethanolamide and Related ALIAmides: Prohomeostatic Lipid Compounds for Animal Health and Wellbeing. Vet. Sci. 2020;7:78. doi: 10.3390/vetsci7020078[↩]
178. Peritore A.F., Siracusa R., Crupi R., Cuzzocrea S. Therapeutic Efficacy of Palmitoylethanolamide and Its New Formulations in Synergy with Different Antioxidant Molecules Present in Diets. Nutrients. 2019;11:2175. doi: 10.3390/nu11092175[↩]
179. D’Amico R., Impellizzeri D., Cuzzocrea S., Di Paola R. ALIAmides Update: Palmitoylethanolamide and Its Formulations on Management of Peripheral Neuropathic Pain. Int. J. Mol. Sci. 2020;21:5330. doi: 10.3390/ijms21155330[↩]
180. Impellizzeri D., Bruschetta G., Cordaro M., Crupi R., Siracusa R., Esposito E., Cuzzocrea S. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J. Neuroinflam. 2014;11:136. doi: 10.1186/s12974-014-0136-0[↩]
181. Schweiger V., Martini A., Bellamoli P., Donadello K., Schievano C., Balzo G.D., Sarzi-Puttini P., Parolini M., Polati E. Ultramicronized Palmitoylethanolamide (um-PEA) as Add-on Treatment in Fibromyalgia Syndrome (FMS): Retrospective Observational Study on 407 Patients. CNS Neurol. Disord. Drug Targets. 2019;18:326–333. doi: 10.2174/1871527318666190227205359[↩]
182. Passavanti M.B., Fiore M., Sansone P., Aurilio C., Pota V., Barbarisi M., Fierro D., Pace M.C. The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to Tapentadol in the treatment of low back pain: A pilot study comparing prospective and retrospective observational arms. BMC Anesth. 2017;17:171. doi: 10.1186/s12871-017-0461-9[↩]
183. Siracusa R., Fusco R., Cordaro M., Peritore A.F., D’Amico R., Gugliandolo E., Crupi R., Genovese T., Evangelista M., Di Paola R., et al. The Protective Effects of Pre- and Post-Administration of Micronized Palmitoylethanolamide Formulation on Postoperative Pain in Rats. Int. J. Mol. Sci. 2020;21:7700. doi: 10.3390/ijms21207700[↩]